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ABSTRACT 
 
 
In order to design better therapeutic strategies, scientists work on understanding 
the interactions that take place at cell level and have an effect on the immune 
system. In order to identify a few possible inhibitors that may be up-regulated in 
tumor environment and that may affect T-cell action, a cellular assay was 
designed. An Interleukin-12 (IL-12)-responsive murine Th1 cell clone called 2D6 
was used as cellular model to study the effects of transforming growth factor-β 
(TGF-β), insulin, and interleukin-6 (IL-6) on the phosphorylation of Signal 
transducer and activator of transcription 4 (STAT4), a key element in IL-12 
signaling. Cells were IL-12-starved for 12 hours and then were treated for 15 
minutes, 1 hour and 2 hours with one of these factors and/or IL-12 and the cell 
samples were analyzed by flow cytometry. In general, TGF-β and insulin had a 
significant effect in the phosphorylation of STAT4 and cell viability particularly 
after 2 hours in cells incubated with these factors only. While more subtle, the 
effects of IL-6 also seemed to be have a stronger effect after 2 hours of 
treatment. The assay designed was able to provide with answers about inhibition 
of IL-12 signaling in a relatively restricted time frame, but more questions need to 
be answered to fully understand the effect of each factor, for which a new 
experimental approach may be needed. 
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CHAPTER ONE: 
INTRODUCTION 
 
As more knowledge is gained on the ins and outs of the immune system it 
becomes more clear that the mechanisms for the defense against disease and 
pathogens engages a plethora of intermolecular interactions that lead to a final effect 
in the organism. Based on these interactions, scientists work on developing 
therapeutic strategies for the treatment of diseases that either trigger or block certain 
interactions at cell level. The design of such molecular triggers/stops (i.e. drugs) 
requires a good understanding of the effects of changes in interactions such as 
protein signaling in order to be able to manipulate them. It is also important to 
visualize the signaling events as part of a whole, and to understand that the 
components may receive signals from more than one source at a time, leading to an 
action that may result from this crosstalk of signals. In order to study this complex of 
signals and responses, a model cell line from the immune system was used to 
develop a cellular assay that would mimic the presence of different factors in the 
tumor microenvironment where there can be overexpression of many molecules, and 
to quantify the inhibiting effect that such factors could have on the cell’s mechanism 
of action.  
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CHAPTER TWO: 
LITERATURE REVIEW 
 
1.1 Innate immune system 
One of nature’s most amazing systems is the complex network that 
encompasses all the structures and processes that take place in an organism to 
protect and defend it from external agents that may pose a threat. The first line of 
defense after the protective barriers (skin, mucus, proteases and gastric acid in 
stomach, etc) have been crossed by pathogens is the innate system that is said to be 
non-specific although triggered when the pattern-recognition receptors (PRRs) 
identify microbes. These PRRs have evolved so that they detect components in 
foreign pathogens, called pathogen-associated molecular patterns (PAMPs) (Kawai, 
Akira 2010). The innate response is also triggered by damaged or stressed cells that 
send a signal of alarm leading to the recruitment of inflammatory cells. 
 
An important component of the innate response is the presence of leukocytes 
such as neutrophils and macrophages, which are phagocytes that attack pathogens 
and kill them by engulfing them or by mere contact. The most common type of 
leukocyte is the neutrophil, and the cells of this type engulf damaged tissue and 
bacteria and secrete proteolytic enzymes to kill microbes (VanderLaan, Reardon 
2005).  
Other important members of the innate response are the mast cells, which are 
cells that are involved in inflammation and hypersensitivity (allergy) reactions. They 
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are mainly activated when degranulated upon cross-linking of the immunoglobulin E 
(IgE) to the antigen receptor (i.e. FcεR1) followed by antigen binding. After this, they 
release the contents of their granules, which are vasoactive substances (i.e. have an 
effect on blood pressure) such as histamines, proteolytic enzymes like tryptase, and 
inflammatory cytokines like tumor necrosis factor-α (TNF- α). They also secrete other 
cytokines (proteins that carry a signal between cells) that can regulate T-cell and 
macrophage responses, such as interleukins 6 and 10 (VanderLaan, Reardon 2005) 
(Galli, Gordon & Wershil 1991). 
Some lymphocytes like the natural killer cells (NK) play an exceptionally 
important role in innate immunity against diseases such as cancer, due to their 
intrinsic ability to lyse tumor cells, hence their name (VanderLaan, Reardon 
2005)(Herberman, Nunn & Lavrin 1975). These cells are important since they provide 
an early response while the adaptive system mounts an effective response 
(Yokoyama, Kim & French 2004). They perform cell-mediated cytotoxicity by 
releasing granules that contain perforin and granzymes; these proteins drill holes in 
cell membranes and lend to the lysis of target cells. NK cells also release cytokines 
that activate other effector cells such as T-lymphocytes (VanderLaan, Reardon 2005).  
 
1.2The bridge between innate and adaptive immunity 
The inflammatory cascade involves several important steps such as the 
presentation of the antigen to T-lymphocytes. Dendritic cells (DCs) are efficient 
antigen-presenting cells that can regulate immune responses to foreign and self-
antigens and have a unique T-cell stimulatory capacity (Heath, Carbone 2009). The 
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immature dendritic cell samples the antigen by internalizing (receptor-mediated 
endocytosis) its particles in the form of vesicles that are subsequently fused with 
lysosomes and broken down. DCs also express Toll-like receptors that, upon 
stimulation, induce dendritic cell maturation. When mature, the cell undergoes a 
decrease in endocytic activity and an increase in the expression of antigen-
presentation molecules (i.e. MHC I and II, CD1), costimulatory molecules and the 
secretion of inflammatory cytokines like Interleukin 12 (IL-12) and tumor-necrosis 
factor- α (TNF-α) (VanderLaan, Reardon 2005)(Iwasaki, Medzhitov 2004)(Bobryshev 
2000).  
An interesting group of the cells that are members of the adaptive immune 
response and have receptors specific to some antigens are γδ T-lymphocytes (see 
Adaptive immune system). They are a small population of T-cells that have limited 
diversity in their receptors, but are thought to be important in the defense against 
certain pathogens and can either activate or suppress other subsets of lymphocytes 
(VanderLaan, Reardon 2005). They produce cytokines that are also produced by the 
other subsets of T-lymphocytes such as interleukin 10 (IL-10) and interferon-γ (IFN-
γ), and unlike traditional αβ T-cells they do not need antigen presentation in the 
context of major histocompatibility complex (MHC) molecules to respond to the 
antigen, which is why they are considered bridging cells in the immune system 
(Aljurf, Ezzat & Mussa M. 2002).  
Another intriguing subset of lymphocytes is that of the NKT cells, characterized 
by expressing the NK cell markers and the T-cell receptors, thus sharing 
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characteristics from both innate immunity and adaptive immunity cell-type members. 
These cells bridge the gap between the early and late immunity by inducing NK cells 
to produce cytokines upon NKT activation, and by promoting B-lymphocyte 
proliferation and antibody production (Galli et al. 2003).  
 
1.3 Adaptive immune system 
The immune system has a highly sophisticated feature that confers organisms 
with protection against infection from most pathogens. The adaptive immune system 
is characterized by a genetically diverse repertoire that allows anticipation to 
pathogen infection by arming each lymphocyte with a unique antigen receptor that 
enables recognition of invaders. The system is not only anticipatory as it also 
remembers previous pathogen encounters that allow repelling a second invasion, or 
quickly elimination of the recurrent invasion by activating a faster and stronger 
immune response (Cooper, Alder 2006).  
 B-lymphocytes play an important role in establishing and maintaining the 
protective immunity, as they produce antibodies, serve as antigen-presenting cells, 
and have other regulatory functions (Cancro et al. 2009). B-cells can internalize the 
antigen via the B-cell receptor so they can present it to T-cells effectively. They also 
express costimulatory molecules so they can activate T-cells recognizing the same 
antigen, and not only produce antibodies but also secrete cytokines such as 
Interleukin-2 (IL-2), Interleukin-6 (IL-6) and Interleukin-12 (IL-12), IFN-γ, transforming 
growth factor-β (TGF-β) and TNF-α (VanderLaan, Reardon 2005). 
T-cells are an important piece in the machinery of adaptive immunity, as they 
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cover a wide range of functions essential to the defense of cells against pathogens, 
such as helping in the maturation of B-cells, preventing auto-immunity and destroying 
tumors and virally-infected cells. Antigen presenting cells (APCs), dendritic cells 
(DCs), B-lymphocytes and macrophages present the antigen in the form of peptides 
on their surface, in the groove of their major histocompatibility complex (MHC) 
molecule for T- cells to recognize them.  Depending on their length (number of 
residues) these peptides can be bound by either the MHC class I molecules (8-9 
residue-peptides) commonly expressed across cell types or to MHC class II 
molecules (13-17 residue-peptides) expressed by APCs only (Rudenski et al. 1991). 
In MHC class I presentation the peptides presented are derived from endogenous 
proteins that have been processed via a ubiquitin-driven proteolytic system. In MHC 
class II presentation, the peptides presented are derived from exogenous proteins, 
internalized via endocytosis and processed via the proteolytic system. Cytotoxic T-
lymphocytes (CTLs) respond to specific epitopes presented through the MHC class I 
pathway. Cluster-of-differentiation-4-positive (CD4+) T-cells respond to specific 
epitopes presented through the MHC class II pathway (Gerloni et al. 2004).  
T-cells may express either a αβ or γδ type of receptor for antigen recognition. 
The αβ receptor recognizes peptides bound to MHC molecules. In contrast, the γδ 
receptor is not as well understood (Chien, Boneville 2006), but is believed to take 
part by constituting a bridge between innate and adaptive immune responses (Aljurf, 
Ezzat & Mussa M. 2002). Cells bearing the αβ T- cell receptor (TCR) can be 
subdivided into cytotoxic and helper T-cells. The latter express the CD4 molecule on 
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their surface and secrete cytokines after interacting with antigens presented by MHC 
class II molecules; they induce B-cells to proliferate and mature so they can produce 
antibodies. The cytotoxic T-cells express cluster-of-differentiation-8 (CD8) on their 
surface, and antigen presented by MHC class I molecules on a cell. Upon activation 
CD8+ T-cells induce apoptosis of the target cell (Davis et al. 2003). Naïve CD4+ T-
cells (i.e. CD-4+ T-cells that have not been exposed to antigen) differentiate into 
various types of helper T-cells (Th), which can be Th1, Th2, Th17 and regulatory T-
cells. Cytokines drive this differentiation into the different subtypes. Th1 cells produce 
IFN-γ, TNF and IL-2, and are important in the defense against intracellular pathogens 
(Wilson, Rowell & Sekimata 2009). Th2 cells mainly produce IL-4, IL-5 and IL-13 and 
are important for antibody-mediated responses for defense against extracellular 
parasites like helminthes. Th2 cells are also responsible for some allergic 
inflammatory diseases such as asthma (Paul, Zhu 2010)(Wilson, Rowell & Sekimata 
2009). The most recently discovered subset of CD4+ helper T-cells, Th17, is said to 
be capable of promoting chronic inflammation and tissue damage (Cua, Tato 2010). 
Th17 produce IL-17A, IL-17F, IL-21, IL-22 and human IL-26.They are believed to 
contribute to defense against extracellular bacteria and fungi (Wilson, Rowell & 
Sekimata 2009). Regulatory T-cells (Treg) have the ability to suppress inflammation 
and induce tolerance by secreting the anti-inflammatory cytokine IL-10 and TGF- β, 
and inhibit the proliferation of naïve T-cells as well as reduce the helper T-cells 
responses(VanderLaan, Reardon 2005).  
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1.4 Phosphorylation of STAT4 
Signal transducer and activator of transcription 4 (STAT4) is a transcription factor 
that is activated by IL-12, and that interacts with DNA sequences in the IFN-γ-
promoter region to increase this gene’s transcription (Figure 1). Several studies have 
found that the activation of STAT4 also increases the expression of the IL-12 
receptors and other cytokine receptors needed for the induction of IFN- γ (Morinobu 
et al. 2002, Lawless et al. 2000). Upon presentation of an infectious antigen, Th1 
cells secrete IFN- γ that induces apoptosis of infected cells, and it has been found 
that IFN- γ produced by these CD4+ T-cells induces apoptosis in tumor cells (Komita 
et al. 2006, Wang et al. 2003).Critical evidence for this is found in studies in which 
tumor-bearing mice have been treated with an anti- IFN-γ monoclonal antibody. This 
treatment inhibited antitumor activity completely (Komita et al. 2006). In fact in an 
IFN- γ-capture assay experiment T-cells that secreted IFN- γ and were enriched in 
vitro proved to have antitumor effectiveness in vivo, showing the strong immune 
power of this cytokine (Becker et al. 2001). For this reason, it is important to screen 
for possible inhibitors that may cause reduced signaling through STAT4 activation, 
and as a consequence, reduced antitumor activity via IFN-γ secretion.  
 
1.5 T-cells and tumor microenvironment 
It is well known that the interactions of tumor cells and their microenvironment 
have an effect on the tumor growth and metastasis. Inflammatory cells, tumor cells 
and connective tissue cells all secrete cytokines that establish a complex network 
and contribute to the number of factors present in the tissue (Ben-Baruch 2003).  The 
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presence of numerous cytokines can lead to a complex environment where the 
immune cells may encounter stimulation and inhibition from different sources, 
yielding results that cannot be modeled as easily due to the presence of main factors 
that cause crosstalk of signaling pathways.  One of the many factors that T-cells 
respond to is IL-12. A known T-cell stimulatory factor and main driver towards Th1 
differentiation, IL-12 is a heterodimer consisting of two disulfide subunits: p35 that is 
similar in sequence to IL-6 and the granulocyte colony stimulating factor (G-CSF), 
and p40 that is highly similar to the IL-6 receptor (IL-6R) and binds to the β2 subunit 
in the IL-12 receptor (IL-12Rβ2)(Ling et al. 1995). IL-12-related species (IL-12p70 
heterodimer, IL-12p40 monomer and IL-12(p40)2 homodimer) are produced mainly 
by DCs, and such production depends on the exposure of the cell to inflammatory 
mediators during differentiation and maturation (Klinke II 2006, Ebner et al. 2001). 
Such mediators could be Interleukin-4 (IL-4), Interferon-γ (IFN- γ), and Prostaglandin 
E2 (PGE2) as a few examples. The stimuli that immature DC receive in the 
peripheral tissues leads to the production of more mediators such as IL-12, either in 
its bioactive form, IL-12p70, or as the antagonizing forms that block the action of the 
bioactive one , IL-12p40 and IL-12(p40)2 (Klinke II 2007). IL-12 activation and 
stimulation leads to the activation of the Janus kinases Jak2 and Tyk2, which in turn 
phosphorylate IL-12R, serving as docking sites for the transcription factor STAT4 to 
be bound and phosphorylated; this is crucial in Th1 differentiation and the 
consequent production of IFN-γ, and thus the consequent effective elimination of 
pathogens and malignant molecules (Morinobu et al. 2002). 
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Th17 cells differentiate form CD4+ T-cell precursors responding to TGF-β and IL-
6 stimulation, which means they are independent of STAT1 and STAT4 signaling (Lee 
et al. 2009). The signaling of IL-6 is coupled to induction of IL-21 through signal 
transducer and activator of transcription 3 (STAT3) activation, which favors the 
development of Th17 cells (Zhou et al. 2007).  Additionally, TGF-β has been shown 
to stimulate Th17 cell development and to suppress Th1 and Th2 development by 
means of inhibiting STAT4 signaling (Mathur et al. 2007). In developing Th17 cells, 
the IL-23 receptor (IL-23R) is induced, whereas in Th1 cells the IL-12Rβ2 is the one 
induced; activation of either of the receptors drives the fate of the helper T cell into 
Th17 or Th1: the IL-12 receptor strongly activates STAT4 signaling and the IL-23 
receptor strongly activates STAT3 signaling (Lee et al. 2009); (Mathur et al. 2007). 
STAT4 signaling has been found to be a very important element in various diseases, 
such as Sézary syndrome (i.e. cutaneous lymphoma) where the absence of the IL-
12Rβ2 leads to reduced STAT4 activation and has been correlated to the disease 
progression (Showe et al. 1999). It has also been identified as a key component for 
the mechanism of action of Chitosan-IFN-γ-pDNA Nanoparticle (CIN) therapy for the 
treatment of allergic asthma (Kumar et al. 2003).  
Besides IL-23, it has been established that IL-6 promotes the differentiation of 
naïve T-cells into B-lymphocyte T helper cells, by leading to secretion of IL-21, 
independently of Th1, Th2, or Th17 functions. It has also been established that IL-6 
in combination with TGF-β prompt the development of Th17 cells via STAT3 
activation (Eddhari et al. 2009). It is known that IL-17 stimulates production of IL-6 in 
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T cells and fibroblasts through a positive-feedback loop (Ogura et al. 2008) and Th17 
cells are believed to promote tumor growth by producing IL-17 that promotes STAT3 
activity and leads to up-regulation of antiapoptotic (i.e. prevent cell’s programmed 
death) and angiogenic (i.e. promote development of vessels) genes (Wang et al. 
2009). In fact, IL-6 has been correlated to resistance to therapy and drug-induced cell 
death in multiple myeloma (Burdelya et al. 2002, Frassanito et al. 2001). Additionally, 
STAT3 responds to IL-6 (Figure 1) by becoming phosphorylated and translocated to 
the nucleus to serve as transcription factor for the suppressor of cytokine signaling 3 
(SOCS3), which competes with STAT4 for binding to the IL-12R, and to the Janus 
kinase 2 (JAK2) that phosphorylates STAT4(Yamamoto et al. 2003). Thus, it can be 
said that stimulation of IL-6 may lead to reduced Th1 immune response by down-
regulating STAT4 signaling.  
A well known strategy for tumor cells to evade immunosurveillance is the down-
regulation of cell surface molecules involved in immune recognition, and the 
overexpression of the immunosuppressive cytokine TGF-β. This cytokine is 
overexpressed by many tumor cells, and it enhances the generation of 
immunosuppressive regulatory T-cells that also produce TGF-β (Nam et al. 2008). In 
addition TGF-β is known to inhibit Th1 responses by shifting T cells towards a Th2 
type, which results in a less efficient immune response against tumor cells (Flavell et 
al. 2010)(Maeda, Shiraishi 1996).  The TGF-β receptor is composed of type I and 
type II receptor serine/threonine kinases on the T-cell surface. After binding of TGF-β 
receptor II phosphorylates receptor I activating it to initiate signaling by 
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phosphorylating Smad and leading to the activation of other kinases (Figure 2)(Shi, 
Massague 2003). TGF-β is also known to inhibit IL-12 signaling in T-cells by 
decreasing the activity of kinases involved in the activation of transcription factors 
such as STATs(Bright, Sriram 1998).  
 
 
Figure 1: Schematics of STAT signaling  
A. Signal transducers and activators of transcription (STAT) proteins are tyrosine 
phosphorylated via Janus kinases (JAKs) at around residue number 700 as a result of 
cytokine-receptor stimulation. STATs also receive stimuli from other receptors in an indirect 
way. B. Phosphatases (a) and supressors of cytokine signaling (SOCS) (b) can block STAT 
access to tyrosine kinase at the receptor, mediate STAT dephosphorylation (c) mediate 
interactions with protein inhibitors of STATs (d) or interfere with transcription by binding DNA 
sequence or activated STAT protein. Source:(Levy, Darnell Jr. 2002). 
 
 
Upon stimulation with insulin, its binding to the insulin receptor triggers the tyrosine 
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kinase activity of the latter, initiating an intracellular signaling cascade where many mitogen-
activated protein kinases (MAPKs) are activated, and the insulin receptor 1 (IRS-1) is the first 
intracellular protein to be phosphorylated (Orcy et al. 2005)(Sykiotis, Papavassiliou 2001). As 
insulin binds its receptor on the cell-surface, the latter becomes autophosphorylated in its β-
subunits and this confers the receptor with tyrosine kinase abilities that phosphorylated insulin 
receptor subtrates-1 and-2 (IRS-1 and IRS-2, respectively) (Figure 3). These phosphorylation 
events generate docking sites for molecules such as phosphatidylinositol-(PI)-3-kinase among 
others, leading ultimately to the stimulation of the MAPK/ERK kinase (MEK) and ERK 
(Desbois-Mouthon et al. 1998).  It is known that phosphorylation of p38 MAPK and c-Jun N-
terminal kinase (JNK) favors T-cell polarization toward Th1, and phosphorylation by 
extracellular-signal regulated kinases (ERK) leads to polarization of T-cells toward Th2(Viardot 
et al. 2007, Dong, Davis & Flavell 2002). As a consequence, continuous activation of the 
insulin pathway that would cause activation of ERK and inhibition of p38 and JNK, would lead 
to favored polarization into Th2 cells, decreasing the IFN-γ to IL-4 ratio as a consequence of 
decreased phosphorylation of STAT4 (Viardot et al. 2007). However it is not clear yet whether 
insulin exerts an inhibitory effect on IL-12 signaling since its role as an inhibitor remains 
relatively unknown.  
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Figure 2. Signaling events downstream of TGF-β association to receptor 
Receptor type II initiates the signaling cascade by phosphorylating receptor I followed by the 
subsequent activation of Smad proteins. Smad 7 regulates signaling by binding to the receptor 
and causing its degradation.  Source:(Izzi, Attisano 2004). 
 
 
Figure 3. Signaling events upon insulin binding at cell surface 
As insulin binds the receptor, the latter becomes activated and phosphorylates insulin 
receptor substrates-1 and-2 initiating a cascade that activates MAP kinases. Source: 
http://sigmaaldrich.com 
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Based on all this evidence suggesting crosstalk of different signaling pathways, it 
was hypothesized that the presence of either TGF-β, IL-6 or insulin at high levels in 
the cell’s environment would lead to decreased STAT4 phosphorylation and in 
consequence, a less functional helper T-cell. The objective of this work was to 
develop an assay to study the effect of some of these factors encountered in tumor 
microenvironment on the immune response of Th1 cells via STAT4 activation, and to 
establish the significance of the presence or not of such crosstalk in the immune 
system. 
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CHAPTER THREE: 
MATERIALS AND METHODS 
 
3.1 Cell lines and tissue culture 
The cell line 2D6, a Th1-cell clone from mice, was kindly provided by Dr. M. 
Grusby (Harvard University, Cambridge, MA, U.S). The cells were kept in 25 cm2 
tissue culture flask with 15ml cell culture media and supplemented with or without 
6.7ng/ml recombinant Mouse IL-12p70 (eBioscience, San Diego, CA, U.S.). The 
tissue culture media consisted of RPMI-1640 supplemented (sRPMI) with 10% Fetal 
Bovine Serum (FBS) (Atlanta Biologicals, Lawrenceville, GA, U.S.), 100 I.U./ml  
Penicillin/Streptomycin, (Biowhittaker, Walkersville, MD, U.S.), 1% of 200mM L-
Glutamine (Mediatech, Manassas, VA, U.S.), 1% of Non-Essential Amino Acids 100X 
(Chemicon International, Temecula, CA, U.S.A.), 1% of 100mM Sodium Pyruvate  
(MP Biomedicals, Solon, OH, U.S.A.), 1% of 1M HEPEs  (Fisher Bioreagents, 
Pittsburgh, PA, U.S.), and 2μl of b-mercaptoethanol (Sigma Chemical, St. Louis, MO, 
U.S.). Tissue culture media was replaced every 24 hours and cells were cultured at 
37ºC with 5% CO2.  
3.2 Antibodies and Reagents 
Purified Hamster Anti-Mouse IL-12 Receptor B2, Fluorescein isothiocyanate 
(FITC)-conjugated Mouse Anti-Armenian and Syrian Hamster IgG1 (G94-56), Alexa 
Fluor 647-conjugated Mouse Anti-Stat4 (pY693), Alexa Fluor 488 Mouse anti-Stat3 
(pY705), BD Phosflow lyse/fix buffer 5X, and BD Phosflow Perm Buffer III were 
purchased from BD Biosciences (San Diego, CA, U.S.). ChromPure Mouse IgG 
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(whole molecule) and ChromPure Rat IgG (whole molecule) were purchased from 
Jackson Immuno Research (West Grove, PA, U.S.). DPBS 1X and RPMI-1640 were 
purchased from Mediatech (Manassas, VA, U.S.). Sodium Azide (Na Azide) was 
purchased from United States Biochemical Corp (Cleveland, OH, U.S.).  
3.3 Stimulation of IL-12 signaling 
 IL-12 and/or other cytokine stimulation: Cells were cultured in 96-well U -bottom 
plate for 12 hours with sRPMI media without IL-12 before stimulation, at a cell density 
of 6 x 104 cells/well. Either different concentrations of IL-12 (10, 40 and 100 ng/ml) or 
10 ng/ml of IL-6, TGF-β or insulin (each alone or together with 40 ng/ml of IL-12), 
were added into IL-12 treatment groups 12 hours later, DPBS was added into 
negative controls. The cells were cultured for 15 minutes, 1 and 2 hours, and 
samples at time --12 hours (before IL-12 depletion) and time 0 (after 12 hours of IL-
12 depletion) were collected.  
 For all situations, at each time point (-12 hours, 0 hours, 15 minutes, 1 hour, 
2 hours) supernatant for each well was taken and stored at -20ºC. Pre-warmed 
Phosflow lyse/fix buffer was added into each well and incubated at 37 ºC for 10 
minutes. Then, 200 μl of DPBS were added into each well. The plates were stored at 
4 ºC until stained for flow cytometry. The experiment was performed in triplicate, cells 
were cultured at 37ºC, and 5% CO2. 
3.4 Flow cytometry  
Flow cytometry is a technique used to analyze large numbers of cells in short 
time (~10,000 cells/s) that relies on hydrodynamic focusing to inject the cell 
suspension into a sheath stream inside a flow cell (Rieseberg et al. 2001). A laser 
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beam is directed toward the cell and the light scattered in all directions is collected by 
filters and detectors. The voltage pulses generated by the light scattering are counted 
and correlated to cell size (small angle of forward scatter) and internal complexity 
and granularity of the cell (large angle or side scatter). Hydrodynamic focusing 
ensures that only one cell at a time passes through the laser beam. Fluorophores 
can be used to label molecules such as antibodies specific to molecules within the 
cell or on its surface as the appropriate laser wavelength will excite it and cause it to 
emit light that can be detected as well. 
Treated cells were prepared, as described in 3.3, and stained with proper 
fluorophore-conjugated antibodies specific for IL12RB2 and phosphorylated STAT4 
(pSTAT4). 
Treated cells were permeabilized by incubating them with chilled Phosflow Perm 
Buffer III for 30 minutes on ice, and subsequently washed twice with ice cold PBSAZ. 
Cells were incubated with ChromPure Mouse IgG and ChromPure Rat IgG (Block 
Reagent) on ice for 15 minutes to block non-specific IgG binding sites. Subsequently, 
the cells were washed with PBSAz once, incubated with appropriate antibodies 
conjugated to a fluorophore (Table 1) for 30 minutes in the dark and at room 
temperature. The same process was repeated for all selected antibodies. Finally, the 
cells were washed with PBSAz three times and transferred into 5ml tubes containing 
PBSAz for flow cytometry analysis. No stain controls were used as negative flow 
cytometry controls, and single stained controls were used to assess the fluorescence 
spill over. To make up for any possible spectral overlap of the fluorescence excitation 
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and emission spectra for the fluorophores used, the spectral spillover was estimated 
as shown in the spillover matrix (Table 2). These values were calculated from single-
stained controls as described by Klinke (Klinke, Brundage 2009). The spillover matrix 
was used to correct raw fluorescent intensity observed in cells stained with more than 
one fluorophore, so that the scatter plots of single stained controls after spectral 
overlap were removed using the compensation matrix. Unstained controls provided 
an estimate of background fluorescence for all the channels. So for instance, after 
compensation for spectral analysis, the sample stained with a fluorescently labeled 
antibody against phosphorylated STAT4 (Alexa Fluor-647) should show an increase 
above background only for the pSTAT4 channel. 
 
 
Table 1. Fluorescence spectra of fluorophores used. 
Fluorophore Excitation peak (nm) Emission peak (nm) 
FITC 495 520 
Alexa Fluor 647 650 668 
 
 
Table 2. Spillover matrix of FITC and Alexa Fluor 647 channels. 
 FITC (IL-12Rβ2) Alexa Fluor 647 (pSTAT4) 
FITC (IL-12Rβ2) 1 0 
Alexa Fluor 647 (pSTAT4) 0 1 
 
 
Data Analysis 
 
The flow cytometry raw data were analyzed with R/Bioconductor (see Appendix 
A) to obtain compensation and transformed values of the median fluorescent 
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intensities for each parameter measured (i.e. pSTAT4). 
A two-way ANOVA was applied at each time point to compare the effect of each 
potential inhibitor to the effect of IL-12 on pSTAT4 median fluorescent values and live 
cell percent values.  P ≤ 0.05 was taken as a point of significance. The statistical 
analysis was done with the Minitab 15 Statistics Software. 
 
3.5 Western Blot 
 
 The Western Blot technique allows the detection of proteins from a tissue or 
extract sample by molecular weight.  Cells are broken by mechanical methods such 
as sonication and detergents and buffers are used to lyse them and solubilize the 
protein sample. The proteins are then separated by gel electrophoresis mostly 
sodium dodecyl sulphate - polyacrylamide gel electrophoresis (SDS-PAGE), in which 
reducing agents are used to denature proteins by removing secondary and tertiary 
structures. The SDS is negatively charged and coats the protein to protect its 
denatured structure, and so the protein migrates through the acrylamide gel towards 
the positively charged electrode. The samples are loaded onto the gel into wells, and 
when voltage is applied the proteins migrate at different velocities according to size 
(i.e. smaller molecular weight proteins migrate faster) separating into bands on a 
lane. Once separated, the proteins are transferred onto a nitrocellulose or 
polyvynilidene difluoride (PVDF) membrane by means of an electric current that pulls 
the proteins into the membrane in the exact same location and distribution they had 
within the gel. The membrane is blocked with a generic protein such as bovine serum 
albumin (BSA) or non-fat dry milk to avoid unspecific binding of antibodies used for 
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detection to the membrane. For detection the membrane is incubated overnight at 
cold temperature in a dilute solution of primary antibody from an animal source that is 
specific to the protein of interest. The membrane is then washed and incubated in a 
dilute solution of secondary antibody directed toward the species of origin of the 
primary antibody. The secondary antibody is usually linked to an enzyme that cleaves 
a chemiluminescent agent so the bound complex can be detected by film exposure. 
Some other secondary antibodies are bound to a fluorophore or fluorescent label so 
a scanner with a CCD camera (i.e.photosensor) that has appropriate emission filters 
can capture a digital image of the membrane for analysis. 
 
 Cells were cultured and treated as explained on section 3.3 for stimulation with 
each potential inhibitor (TGF-β, insulin, IL-6) at a cell density of 6 x107/ml. Cells were 
pelleted and resuspended in 1 ml of cold DPBS. Then the cell suspension was 
centrifuged for 30 seconds and pelleted again, and the pellet was resuspended in 
500 μl of cold Cell Lysis Buffer (90% double distilled water, 2% 1M Tris (pH 7.66), 3% 
5M NaCl, 0.2% 0.5M EDTA, 1% 0.1M EGTA, 1% Triton X-100, 2.5 % 0.1M Sodium 
pyrophosphate, 0.5% Sodium orthovanadate,  2.5% 1mg/ml leupeptin) and incubated 
on ice for 5 minutes. Cells were then sonicated 4 times for 5 seconds each, and 
centrifuged for 10 minutes at 4°C. The supernatants were transferred to new tubes 
(around 250 μl per tube) and the lysates were stored at -70°C. The lysates were 
loaded onto an acrylamide gel together with a Stat3 control cell extract (Cell 
Signaling Technology, Inc.) and a molecular weight marker (Odysssey Two-Color 
Protein Molecular Weight Marker, Li-Cor Biosciences, Lincoln, Nebraska, USA). The 
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lysates were separated by gel electrophoresis and blotted onto a PVDF membrane 
(see Appendix D).  The membrane was blocked with Odyssey® Blocking Buffer (Li-
Cor Biosciences, Lincoln, Nebraska, USA) and probed with antibodies against 
pSTAT3 and an antibody against glyceraldehyde 3-phosphate dehydrogenase 
(GAPDH) as a loading control (GAPDH (FL-335), Santa Cruz Biotechnology, Inc., 
Santa Cruz, California, USA). Phosphorylated STAT3 was detected by use of a rabbit 
anti-Phospho STAT3 (Y705) (Cell Signaling Technology, Inc.) primary antibody, and 
IRDye® 800CW Conjugated Goat (polyclonal) anti-rabbit IgG secondary antibody. 
The proteins were imaged with the Odyssey® Infrared Imaging System (Li-Cor 
Biosciences, Lincoln, Nebraska, USA).  
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CHAPTER FOUR: 
RESULTS AND DISCUSSION 
 
 
4.1 Effect of potential inhibitors on STAT4 phosphorylation 
 
In order to address the response of T cells to the presence of possible inhibitors in 
the tumor microenvironment, the 2D6 cell line derived from a mouse Th1 cell clone 
was cultured at a cell density of 6 x 104 cells/well and deprived of IL-12 for a period of 
12 hours. Following this period of starvation, they divided into four treatment groups: 
treated with IL-12 only, treated with the potential inhibitor of STAT4 phosphorylation 
(i.e. TGF-β, Insulin, IL-6) only, treated with both insulin and the potential inhibitor, or 
with no treatment. The appropriate cells were stimulated with either 10 ng/ml TGF-β 
(Zheng et al. 2002),(Hanafusa et al. 1999), 10 ng/ml insulin (Viardot et al. 2007) or 10 
ng/ml IL-6 (Nakagawa et al. 2009)(Takeda et al. 1998) for 15 minutes, 1 hour or two 
hours. The results are representative of at least two biological replicates.  
 
4.1.1 Gating for cell population 
 
To exclude dead cells and non-cellular debris from the flow cytometric analysis, the 
forward and side scatter characteristics of the observed events for each sample was 
used to identify live cells by means of R/Bioconductor analysis. Reduced cell size 
(i.e., reduced forward scatter) and an increase in cellular granularity (i.e., an increase 
in side scatter) correlate with cell death. As a representative sample, the forward and 
side scatter plot for cells at -12 hours (i.e. cells before IL-12 depletion) is shown in 
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Figure 4. Live cells used in subsequent analysis were identified using a data-driven 
gate as enclosed by the red circle: the blue dots stand for each individual cell, the red 
circle encloses 95% of the population used for subsequent analysis.  
 
Figure 4. Forward and side scatter of 2D6 cells at time -12 hours (i.e. before IL-12 
starvation). 
Blue dots represent individual cells, and 95% of the population used for analysis is 
enclosed in the red circle. 
4.1.2. Response of 2D6 cells to cytokine stimuli 
To assess for the optimal dose of IL-12 to obtain a maximum response of the IL-
12 signaling pathway in 2D6 cells, the activation of STAT4 was measured after 
stimulation with different concentrations of IL-12. Such parameter was measured by 
flow cytometry using an antibody for the phosphorylated STAT4 (Table 1). The 
optimal concentration determined was used in subsequent experiments. 
Since the levels of expression of IL-12Rβ2 correlate positively with STAT4 
activation upon IL-12 stimulation as found in a previous study from our research 
group (Finley et al. 2010), the presence of IL-12Rβ2 was observed in each 
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experiment as a internal control by flow cytometry using the appropriate antibodies 
(Table 1).  
A statistical data-driven threshold was used to define the background level of 
fluorescence associated with IL12R β2 and pSTAT4, using unstained cells, and 
single stain controls for each (See Appendix B). The positive thresholds for IL12R β2 
and pSTAT4 were defined as the level of fluorescence for which 95% of the un-
stimulated cells exhibited a lower level of fluorescence. In general the distribution in 
Median fluorescent Intensities (MFIs) associated with IL12Rβ2 and pSTAT4 exhibited 
unimodal distributions, as depicted by the single-stain controls used for the 
thresholds (Figure 6). Median value of these unimodal distributions were 
subsequently used to summarize dynamic changes in components of the IL-12 
signaling pathway. 
Following IL-12 starvation for 12 hours, samples were collected from the 
treatment groups at 0, 15 minutes, 1 and 2 hours. A representative scatter plot of the 
Median fluorescent Intensity (MFI) for pSTAT4 versus IL12Rβ2 is shown in Figure 6 
where the MFI associated with phosphorylated STAT4 was correlated with IL12Rβ2 
positive cells.  
 
Dose response 
 
In order to establish the concentration of IL-12 to treat the 2D6 cell, a dose response 
was done, to evaluate the concentration for which the maximum STAT4 activation 
was obtained (Figure 5). Based on that, and previous findings, the concentration of 
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IL-12 used across all the experiments was 40 ng/ml. 
 
Figure 5. Dose response curve. 
Response values were recorded using different concentrations of IL-12, where the response 
(R) corresponds to phosphorylated STAT4 upon IL-12 stimulation of 2D6 T-cells. 
 
Figure 6. Single stain control histograms. 
The left panel shows the histogram for pSTAT4 mean fluorescent intensity (MFI), where MFI 
of pSTAT4 is the x-axis and normalized cell density is the y-axis. The right panel shows the 
histogram for IL-12Rβ2 mean fluorescent intensity (MFI), where MFI of IL-12Rβ2 is the x-axis 
and normalized cell density is the y-axis. The gray polygon represents no stain control (i.e. 
6x104 cells/well treated with IL-12 and no fluorescent stain), the red line represents the single 
stain control for pSTAT4 (i.e. 6x104 cells/well treated with IL-12 and Alexa Fluor 647 anti-
pSTAT4 antibody), and the black line represents the single stain control for IL-12Rβ2 (i.e. 
6x104 cells/well treated with IL-12 and FITC anti- IL-12Rβ2 antibody). 
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Figure 7. Representative plot of phosphorylated STAT4 versus IL-12Rβ2 upon 
stimulation with 40 ng/ml of IL-12 for 1 hour. 
The scatter plot (C) represent the cell population distribution for expression of pSTAT4 and IL-
12R β2. The vertical solid line represents the positive threshold for IL-12R β2 expression 
observed as the vertical dashed line in panel A, and the horizontal dashed line represents the 
positive threshold for pSTAT4 expression observed as a vertical dashed line in panel B. cells 
positive for both molecules appear in the upper right quadrant of panel C. 
 
 
4.1.3. Effect of TGF-β on STAT4 phosphorylation 
 
The time course in the expression of pSTAT4 in 2D6 cells upon stimulation with 
TGF-β is depicted in Figure 8. In general the most significant effect with respect to 
the unstimulated group was observed in the cells stimulated with TGF-β (Table 3) 
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particularly after two hours of incubation (See Appendix C). A decreasing trend in 
STAT4 phosphorylation is followed after 15 minutes and continues with time in the 
group treated with TGF-β only, comparable to the trend followed by the unstimulated 
group. The lowest value of phosphorylation of STAT4 was reached by the latter after 
2 hours of incubation (mean=44.08). The highest MFI values are displayed by the 
group treated with IL-12 and TGF-β, reaching a peak of STAT4 activation at 1 hour 
(mean=106.36) followed by a subtle decrease at 2 hours (mean=101.15). A similar 
trend was observed for the group treated with IL-12 only, where stimulation by this 
cytokine proved to have a significant effect as well on STAT4 phosphorylation (Table 
3). 
 
 
Figure 8. Time course of pSTAT4 expression in different treatment groups with TGF-β. 
2D6 cell groups plated at a density of 6 x 104 cells/well were stimulated with 10 ng/ml of TGF-
β (cross marks), 40 ng/ml of IL-12 ( triangles), with both TGF-β and IL-12(squares) or left 
untreated (diamonds), and allowed to remain in culture for 15 minutes, 1 hour and 2 hours. 
Means of MFI values of pSTAT4 are shown above. 
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Table 3. P-values from two-way ANOVA for analysis of TGF-β experiments. 
 STAT4 phosphorylation Cell viability 
Time IL-12 TGF-β Interaction IL-12 TGF-β Interaction 
15 min <0.001 0.031 0.077 0.237 0.939 0.265 
1 hour 0.136 0.262 0.605 0.758 0.014 0.12 
2 hours  <0.001 <0.001 <0.001 0.011 0.001 0.005 
 
 
Figure 9. Median fluorescent intensities of pSTAT4 per time point. 
The bars represent the MFI values of phosphorylated pSTAT4 at each time point for each of 
the treatments: cells stimulated with 10 ng/ml of TGF-β (diagonal-line pattern), 40 ng/ml of IL-
12 (yellow, no pattern), with both TGF-β and IL-12(plaid pattern) or left untreated (dotted 
pattern), and allowed to remain in culture for the indicated times. Means of MFI values of 
pSTAT4 are shown above. The asterisks show the time points at which significant differences 
with respect to the unstimulated group were observed (Table 3).  
 
 
 
Effect of TGF-β on cell viability 
 
The time course in the viability of the 2D6 treatment groups is depicted in Figure 
10.  The values of cell viability (i.e. live cell percent) were analyzed for each time 
point to compare across treatments. In general all treatment groups displayed a 
subtle decreasing trend in viability with increasing time, except for the untreated 
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group where a peak in live cell percent was observed at 1 hour after time 0 (mean= 
29.05). The lowest mean value for live cell percent was reached by the group treated 
with TGF-β only after 2 hours (mean=5.27) (Figures 10,11). 
 
Figure 10. Time course of cell viability in different treatment groups of TGF-β. 
2D6 cell groups plated at a density of 6 x 104 cells/well were stimulated with 10 ng/ml of TGF-
β (cross marks), 40 ng/ml of IL-12 ( triangles), with both TGF-β and IL-12(squares) or left 
untreated (diamonds), and allowed to remain in culture for 15 minutes, 1 hour and 2 hours. 
Means of live cell percent values are shown above. 
 
Figure 11. Cell viability per time point. 
The bars represent the values of live cell percent at each time point for each of the 
treatments: cells stimulated with 10 ng/ml of TGF-β (diagonal-line pattern), 40 ng/ml of IL-12 
(yellow, no pattern), with both TGF-β and IL-12(plaid pattern) or left untreated (dotted pattern), 
and allowed to remain in culture for the indicated times. Means of live cell percent values are 
shown above. The asterisks show the time points at which significant differences with respect 
to the unstimulated group were observed (Table 3).  
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4.1.3.1. Discussion 
 
Transforming growth factor-β has been previously shown to inhibit IL-12 
signaling (Bright, Sriram 1998, Pardoux et al. 1999). Pardoux et al. observed that 
treatment with TGF-β for 20 minutes inhibited STAT4 phosphorylation significantly in 
human T-cells, the same Bright and Sriram found in mouse T-cells. However, in the 
present study the strongest inhibitory effect of TGF-β was observed after incubation 
for 2 hours suggesting that time frame for the effect of this protein on the model cell 
line used may be longer than in vivo. Other STAT proteins like STAT1 exhibit rapid 
activation and deactivation kinetics with a half life of approximately 15 minutes(Lim, 
Cao 2006). The results in this study show that stimulation with IL-12 yields a peak of 
pSTAT4 after an hour of incubation (Figure 8). This observed delay in the stimulatory 
effects of IL-12 may be common to other effects in this cell line, or it is possible that 
TGF-β has a delayed onset of action in these cells. However the inhibitory effect was 
observed only in the cells stimulated with TGF-β only, not in the ones stimulated with 
both TGF-β and IL-12, in fact, the highest STAT4 activation was accomplished in the 
by this group suggesting a synergistic effect of TGF-β  and IL-12 in the 2D6 cells. 
Bright and Sriram conducted a study on the effect of TGF-β on murine T-cells, and 
found that it inhibited the activity of Janus kinase-2 (JaK-2) and Tyrosine kinase-2 
(Tyk-2) to a great extent, causing the inhibition of STAT4 phosphorylation as well 
(Bright, Sriram 1998). However, Sudarshan et al found that TGF-β had no effect on 
the activation of JaK-2 and Tyk-2, and did not inhibit STAT4 phosphorylation by these 
kinases (Sudarshan et al. 1999).  The TGF-β ligand starts signaling by bringing 
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together type I and type II receptor serine/threonine kinases as it binds them at the 
surface of the T-cell. Receptor II phosphorylates the kinase domain in receptor I and 
the activated receptor subsequently phosphorylates Smad proteins (Shi, Massague 
2003). Active STAT4 promotes the expression of Smad7, a regulatory protein that 
antagonizes TGF-β signaling (Letterio 2005, Soto, Price-Schiavi & Carraway 2003). 
This would explain the observed synergy between IL-12 and TGF-β. An increase on 
Smad 7 in 2D6 cells upon stimulation with IL-12 would support the hypothesis. 
Another interesting effect observed after incubation with TGF-β was the 
increased reduction of cell viability after 2 hours of incubation with TGF-β only 
(Figure 9). TGF-β has been linked to apoptosis in several studies. The mechanism of 
action includes the expression of cyclin-dependent kinases (CDKs) that inactivate 
proteins important for cell survival, and the expression of death-associated protein 
(DAP) kinase (Jang et al. 2002). The increased variability in the effects after 2 hours 
of TGF-β alone (Figure 9 and Appendix C) on both STAT4 activation and viability may 
be a result of the extensive amount of cross-talk that takes place in TGF-β signaling 
once it reaches the level of Smads (Massague 2000). This cross-talk is additionally 
enhanced by the cooperative actions of Smads in the nucleus for the transcription of 
several target genes that are transcribed depending on the cell type and its metabolic 
needs (Jang et al. 2002). Observing changes in associated signaling proteins may 
help inform on the mechanisms that TGF-β uses to promote apoptosis. 
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4.1.4. Effect of insulin on STAT4 phosphorylation 
 
The time course in the expression of pSTAT4 in 2D6 cells upon stimulation with 
insulin is shown in Figure 12. The MFI values of STAT4 phosphorylation were 
analyzed for each time point to compare across treatments (see Appendix C), 
Significant differences with respect to the unstimulated group were observed mainly 
due to IL-12 stimulation at all time points (Table 4). Insulin only had a significant 
effect on 2D6 cell after 1 hour of treatment and in the presence of IL-12, while the cell 
group stimulated with insulin only displayed a very similar trend to the unstimulated 
group maintaining close MFI values through the 2 hours. The highest MFI value for 
STAT4 activation was observed after 1 hour of incubation in the group treated with IL-
12 and insulin (mean=94.9) (Figure 13). 
 
Figure 12. Time course of pSTAT4 expression in different treatment groups with insulin 
2D6 cell groups plated at a density of 6 x 104 cells/well were stimulated with 10 ng/ml of 
insulin (cross marks), 40 ng/ml of IL-12 ( triangles), with both insulin and IL-12(squares) or left 
untreated (diamonds), and allowed to remain in culture for 15 minutes, 1 hour and 2 hours. 
Means of MFI values of pSTAT4 are shown above. 
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Table 4. P-values from two-way ANOVA for analysis of insulin experiments. 
 STAT4 phosphorylation Cell viability 
Time IL-12 Insulin Interaction IL-12 Insulin Interaction 
15 min 0.016 0.694 0.141 0.311 0.995 0.379 
1 hour <0.001 0.033 0.005 0.197 0.043 0.606 
2 hours  <0.001 0.484 0.002 0.106 0.374 0.048 
 
 
Figure 13. Median fluorescent intensities of pSTAT4 per time point. 
The bars represent the MFI values of phosphorylated pSTAT4 at each time point for each of 
the treatments: cells stimulated with 10 ng/ml of insulin (diagonal-line pattern), 40 ng/ml of IL-
12 (yellow, no pattern), with both insulin and IL-12(plaid pattern) or left untreated (dotted 
pattern), and allowed to remain in culture for the indicated times. Means of MFI values of 
pSTAT4 are shown above. The asterisks show the time points at which significant differences 
with respect to the unstimulated group were observed (Table 4).  
 
 
Effect of insulin on cell viability 
 
.All treatment groups exhibited a subtle increase in viability at 1 hour followed by a 
decrease except for the untreated group where the live cell percent continued to 
increase in time(Figures 14, 15). The highest percent of live cells was observed at 1 
hour in the group treated with both insulin and IL-12 (mean=33.62). In general 
treatments no effect on cell viability, except for the group treated with insulin where 
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statistically significant difference with respect to the unstimulated group was 
observed (Table 4).  
 
Figure 14. Time course of cell viability in different treatment groups of insulin 
2D6 cell groups plated at a density of 6 x 104 cells/well were stimulated with 10 ng/ml of 
insulin (cross marks), 40 ng/ml of IL-12 ( triangles), with both insulin and IL-12(squares) or left 
untreated (diamonds), and allowed to remain in culture for 15 minutes, 1 hour and 2 hours. 
Means of live cell percent values are shown above. 
 
Figure 15.  Cell viability per time point. 
The bars represent the values of live cell percent at each time point for each of the 
treatments: cells stimulated with 10 ng/ml of insulin (diagonal-line pattern), 40 ng/ml of IL-12 
(yellow, no pattern), with both insulin and IL-12(plaid pattern) or left untreated (dotted pattern), 
and allowed to remain in culture for the indicated times. Means of live cell percent values are 
shown above. The asterisks show the time points at which significant differences with respect 
to the unstimulated group were observed (Table 4).  
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4.1.4.1 Discussion 
 
In the present study the relationship between stimulation with insulin and IL-12 
signaling in the Th1 cell line, 2D6, was shown for the first time. Viardot et al. found 
that insulin promoted Th2 differentiation by reducing the IFN-γ (i.e. cytokine produced 
by Th1 cells) to IL-4 (i.e. cytokine produced by Th2 cells) ratio in vitro in human 
peripheral blood mononuclear cells (PBMC)(Viardot et al. 2007). These findings 
coincide with a reduction in STAT4 phosphorylation in the 2D6 cell line after 
incubating with insulin only for 1 and 2 hours. However, the fact that an up-regulating 
effect in STAT4 phosphorylation was observed in the present study after 15 minutes 
and 1 hour of incubation, it is possible that insulin participates in a pathway that 
cooperates synergistically with IL-12 to activate STAT4. However, considering the 
activation of STAT4 peaks at 1 hour across treatment groups and then decreases 
and that in Viardot’s study the cells were treated for 72 hours, it is possible that a 
more pronounced effect may be observed with the 2D6 cells in culture with insulin 
within a larger time frame.  
  A similar increasing trend peaking at 1 hour was observed for the cell viability. 
Although to a subtle extent, the increased viability is in agreement with Viardot’s 
observations of insulin inhibiting apoptosis in CD4+ T-cells (Viardot et al. 2007). This 
is also consistent with another study on cells from a murine T-cell line, A1.1, where 
up-regulated levels of IRS-1 correlated with an inhibition of apoptotic signaling events 
due to activation-induced cell death (AICD) (Li et al. 2002)and with the inhibition of 
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apoptosis observed in vascular smooth muscle cells(Allen et al. 2005). In general, 
future experiments increasing the exposure time are recommended to observe the 
effects of insulin over a larger time frame.  
 
4.1.5. Effect of IL-6 on STAT4 phosphorylation 
 Based on knowledge about the degree of homology between STAT3 and STAT4 
the 2D6 cell line was also used to identify signaling cross-talk between IL-12 and IL-
6. (Levy, Darnell Jr. 2002); (Zhong, Wen & Darnell 1994)Phosphorylation of STAT4 
was used as an indication of IL-12 activation while pSTAT3 was used as a positive 
control for IL-6 activation. Unfortunately no pSTAT3 was observed in response to IL-6 
stimulation (data not shown).  In general there was no significant effect of IL-6 on the 
2D6 cells at any time point, and the only significant differences with respect to the 
unstimulated group were due to treatment with IL-12 after 1 and 2 hours of 
incubation(Table 5) (Figures 16, 17). There was no significant effect of IL-12 or IL-6 
on viability in these experiments (Table 5). 
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Figure 16. Time course of pSTAT4 expression in different treatment groups with 
insulin. 
2D6 cell groups plated at a density of 6 x 104 cells/well were stimulated with 10 ng/ml of 
insulin (cross marks), 40 ng/ml of IL-12 ( triangles), with both insulin and IL-12(squares) or left 
untreated (diamonds), and allowed to remain in culture for 15 minutes, 1 hour and 2 hours. 
Means of MFI values of pSTAT4 are shown above. 
 
 
 
 
Table 5. P-values from two-way ANOVA for analysis of IL-6 experiments. 
 STAT4 phosphorylation Cell viability 
Time IL-12 IL-6 Interaction IL-12 IL-6 Interaction 
15 min 0.946 0.075 0.364 0.994 0.798 0.477 
1 hour 0.027 0.794 0.001 0.103 0.092 0.195 
2 hours  0.035 0.167 0.003 0.423 0.21 0.129 
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Figure 17. Median fluorescent intensities of pSTAT4 per time point. 
The bars represent the MFI values of phosphorylated pSTAT4 at each time point for each of 
the treatments: cells stimulated with 10 ng/ml of IL-6 (diagonal-line pattern), 40 ng/ml of IL-12 
(yellow, no pattern), with both IL-6 and IL-12(plaid pattern) or left untreated (dotted pattern), 
and allowed to remain in culture for the indicated times. Means of MFI values of pSTAT4 are 
shown above. The asterisks show the time points at which significant differences with respect 
to the unstimulated group were observed (Table 5). 
 
 
Figure 18. Time course of cell viability in different treatment groups of IL-6. 
2D6 cell groups plated at a density of 6 x 104 cells/well were stimulated with 10 ng/ml of IL-6 
(cross marks), 40 ng/ml of IL-12 ( triangles), with both IL-6 and IL-12(squares) or left 
untreated (diamonds), and allowed to remain in culture for 15 minutes, 1 hour and 2 hours. 
Means of live cell percent values are shown above. 
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Figure 19. Cell viability per time point. 
The bars represent the values of live cell percent at each time point for each of the 
treatments: cells stimulated with 10 ng/ml of IL-6 (diagonal-line pattern), 40 ng/ml of IL-12 
(yellow, no pattern), with both IL-6 and IL-12(plaid pattern) or left untreated (dotted pattern), 
and allowed to remain in culture for the indicated times. Means of live cell percent values are 
shown above. The asterisks show the time points at which significant differences with respect 
to the unstimulated group were observed (Table 4).  
 
 
4.1.5.1 Discussion 
 
The lack of observed pSTAT3 in the experiments in this study lead to a first 
conclusion about the phosphorylation of STAT3: based on the degree of homology of 
STAT3 and STAT4 it was possible that all the phosphorylated STAT3 was being 
bound by the pSTAT4 antibody. This together with the fact that inhibiting effects of IL-
6 in the present study appear to be more subtle than expected, lead to ask the 
question of whether STAT3 was being activated upon stimulation with IL-6 or not. 
Western Blot experiments performed as indicated (See Appendix D) were conducted 
to observe the phosphorylated STAT3 in the 2D6 cells after treatment with IL-6 and/or 
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IL-12 (Figure 17).  The fact that no phosphorylated STAT3 was observed after the 
Western Blot experiments suggested that STAT3 was not being activated at all by IL-
6 in these cells. Ahn et al (Ahn et al. 1998)observed phosphorylated STAT3 in 2D6 
cells upon stimulation with IL-12; however, considering the responsiveness of the cell 
line to this interleukin, it is possible that the STAT3 observed was STAT4 that was 
bound non-specifically. A possible explanation could be that pSTAT3 is being 
deactivated before detection by cross-talk with an inhibiting pathway or could be all 
activated by IL-12 prior to the experiment. 
 
 
Figure 20. Western blot to observe pSTAT3 in 2D6 cells upon treatment with IL-6. 
Cells were treated as they were for the previous experiments (see Materials and Methods) 
and lysed for protein separation by gel electrophoresis. The gel was blotted onto a membrane 
that was probed with antibodies against phosphorylated STAT3 (See Appendix D). 
 
Sengupta et al. found that in human myeloid cells the phosphorylation of STAT3 
was inhibited within 5 minutes upon IL-6 stimulation by the action of MEK and ERK 
kinases that act by blocking the signaling pathway upstream of STAT3 activation 
(Sengupta et al. 1998). It is possible that the MEK-ERK signaling pathway is being 
activated and is inhibiting phosphorylation of STAT3 as an early event during the 
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incubation time.  
The IL-6 receptor is composed of a ligand-binding α-chain and the signal 
transducer gp130 that contains six tyrosines in its cytoplasmic region, among which 
Tyr 759 is required for activation via STAT3 of SOCS3, which is STAT proteins’ 
competitor for binding the IL-12 receptor and for phosphorylation by Jak-2(Yamamoto 
et al. 2003, Nishihara et al. 2007). It is also possible that the 2D6 cell line does not 
express the IL-6 receptor on its surface, rendering the cell unresponsive to IL-6 
mediated signal for activation. In recent unpublished work in our research group it 
was found that these cells do not respond to stimulation with IFN-γ (data not shown), 
so perhaps they do not respond to IL-6 either. Verification of the presence of the IL-6 
receptor, namely the g130 signal transducer on the surface of 2D6 Th1 cells should 
provide more insight into the lack of an observed effect of IL-6 on these cells. 
 
4.2 Conclusion 
The assay allowed the observation of a significant inhibition exerted by TGF-β on 
2D6 cells. Subtle effects were observed when the cell groups were incubated with 
insulin, however the cross-talk between insulin and IL-12 signaling remains unclear. It 
is necessary to observe the effects on more proteins downstream the receptor (e.g. 
IRS-1) to understand the phenomenon. In addition longer incubation times may allow 
the observation of a more significant effect.  
Regarding cross-talk between IL-6 and IL-12, It is possible that the 2D6 cell line 
does not respond to IL-6 due to a lack of receptor expression. Either using more than 
one cell model or a different one, or studying the effect on other molecules 
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downstream of inhibitor-binding to cell surface is recommended for future 
experiments.  
In general the assay designed was able to provide with answers about inhibitiory 
effects of the factors studied on IL-12 signaling despite a relatively restricted time frame. 
However, more questions need to be answered to fully understand the effect of each 
factor. 
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APPENDIX A 
 
Sample R/Bioconductor code for analysis of data 
 
#In this experiment, we starved the 2D6 cells for 12 hours without 
IL-12,prior to stimulation with insulin.  
#The cell line used is the 2D6 cell line, a T helper cell line.  The 
cells were  
#stained for IL-12R$\beta$2, and pSTAT4 at time 0hr,-
12hr,15min,1hr,2hr following the addition of insulin and/or IL-12. 
#The concentrations of IL-12, aliquoted in BSA, is 40ng/ml. Cell 
density and ratio of 2D6 and B16 changes.  
#normally 2D6 at 6 x 10^4 cell$/well$, 2-stand for 2D6 at 1.2 x 10^5 
cell$/well$.     
 
library(flowCore)  
library(flowViz)  
library(flowUtils)  
library(geneplotter)  
library(colorspace) 
library(grid) 
library(MASS)  
 
memory.limit(size=2000)  
memory.size(max = FALSE) 
 
fclist <- c("./data102610/01-T0-ds-1.fcs", 
           "./data102610/02-T0-ds-2.fcs", 
           "./data102610/03-T0-ds-3.fcs", 
           "./data102610/04-T-12h-ds-1.fcs", 
           "./data102610/05-T-12h-ds-2.fcs", 
           "./data102610/06-T-12h-ds-3.fcs", 
           "./data102610/07-T15m-IL12-Ins-ds-1.fcs",  
           "./data102610/08-T15m-IL12-Ins-ds-2.fcs", 
           "./data102610/09-T15m-IL12-Ins-ds-3.fcs", 
           "./data102610/10-T15m-Ins-ds-1.fcs",  
           "./data102610/11-T15m-Ins-ds-2.fcs", 
           "./data102610/12-T15m-Ins-ds-3.fcs",  
           "./data102610/13-T15m-IL12-ds-1.fcs", 
           "./data102610/14-T15m-IL12-ds-2.fcs", 
           "./data102610/15-T15m-IL12-ds-3.fcs", 
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           "./data102610/16-T15m-nostim-ds-1.fcs", 
           "./data102610/17-T15m-nostim-ds-2.fcs", 
           "./data102610/18-T15m-nostim-ds-3.fcs", 
           "./data102610/19-T1h-IL12-Ins-ds-1.fcs",  
           "./data102610/20-T1h-IL12-Ins-ds-2.fcs", 
           "./data102610/21-T1h-IL12-Ins-ds-3.fcs", 
           "./data102610/22-T1h-Ins-ds-1.fcs",  
           "./data102610/23-T1h-Ins-ds-2.fcs", 
           "./data102610/24-T1h-Ins-ds-3.fcs",  
           "./data102610/25-T1h-IL12-ds-1.fcs", 
           "./data102610/26-T1h-IL12-ds-2.fcs", 
           "./data102610/27-T1h-IL12-ds-3.fcs", 
           "./data102610/28-T1h-nostim-ds-1.fcs", 
           "./data102610/29-T1h-nostim-ds-2.fcs", 
           "./data102610/30-T1h-nostim-ds-3.fcs", 
           "./data102610/31-T2h-IL12-Ins-ds-1.fcs",  
           "./data102610/32-T2h-IL12-Ins-ds-2.fcs", 
           "./data102610/33-T2h-IL12-Ins-ds-3.fcs", 
           "./data102610/34-T2h-Ins-ds-1.fcs",  
           "./data102610/35-T2h-Ins-ds-2.fcs", 
           "./data102610/36-T2h-Ins-ds-3.fcs",  
           "./data102610/37-T2h-IL12-ds-1.fcs", 
           "./data102610/38-T2h-IL12-ds-2.fcs", 
           "./data102610/39-T2h-IL12-ds-3.fcs", 
           "./data102610/40-T2h-nostim-ds-1.fcs", 
           "./data102610/41-T2h-nostim-ds-2.fcs", 
           "./data102610/42-T2h-nostim-ds-3.fcs" ) 
#for compensation matrix only -com 
fclistcom <- c("./data102610/T15m-ns-control.fcs", 
               "./data102610/T15m-ss-IL12RB2.fcs",  
               "./data102610/T15m-ss-pSTAT4.fcs") 
  
fs <- read.flowSet(fclist, transformation = FALSE)  
fscom <- read.flowSet(fclistcom, transformation = FALSE)  
 
Tclist <- c("01-T0-ds-1", 
            "02-T0-ds-2", 
            "03-T0-ds-3", 
            "04-T-12h-ds-1", 
            "05-T-12h-ds-2", 
            "06-T-12h-ds-3", 
            "07-T15m-IL12-Ins-ds-1",  
            "08-T15m-IL12-Ins-ds-2", 
            "09-T15m-IL12-Ins-ds-3", 
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            "10-T15m-Ins-ds-1",  
            "11-T15m-Ins-ds-2", 
            "12-T15m-Ins-ds-3",  
            "13-T15m-IL12-ds-1", 
            "14-T15m-IL12-ds-2", 
            "15-T15m-IL12-ds-3", 
            "16-T15m-nostim-ds-1", 
            "17-T15m-nostim-ds-2", 
            "18-T15m-nostim-ds-3", 
            "19-T1h-IL12-Ins-ds-1",  
            "20-T1h-IL12-Ins-ds-2", 
            "21-T1h-IL12-Ins-ds-3", 
            "22-T1h-Ins-ds-1",  
            "23-T1h-Ins-ds-2", 
            "24-T1h-Ins-ds-3",  
            "25-T1h-IL12-ds-1", 
            "26-T1h-IL12-ds-2", 
            "27-T1h-IL12-ds-3", 
            "28-T1h-nostim-ds-1", 
            "29-T1h-nostim-ds-2", 
            "30-T1h-nostim-ds-3", 
            "31-T2h-IL12-Ins-ds-1",  
            "32-T2h-IL12-Ins-ds-2", 
            "33-T2h-IL12-Ins-ds-3", 
            "34-T2h-Ins-ds-1",  
            "35-T2h-Ins-ds-2", 
            "36-T2h-Ins-ds-3",  
            "37-T2h-IL12-ds-1", 
            "38-T2h-IL12-ds-2", 
            "39-T2h-IL12-ds-3", 
            "40-T2h-nostim-ds-1", 
            "41-T2h-nostim-ds-2", 
            "42-T1h-nostim-ds-3") 
 
 
Tclistcom <- c("T15m-ns-control",  
               "T15m-ss-IL12RB2",  
               "T15m-ss-pSTAT4")  
 
rectGate <- rectangleGate(filterId="FSC+",`FSC-A`=c(31000,Inf))  
#rectCD45Gate <- rectangleGate(filterId=" PerCP-Cy5-5-A+",`PerCP-Cy5-
5-A`=c(100,Inf)) 
morphGate <- norm2Filter(filterId = "MorphologyGate", "FSC-A", "SSC-
A", scale = 2) 
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#KMGate <- kmeansFilter(filterId ="kmfilt1", `LD` = c("Low","High")) 
rectGate2 <- rectangleGate(filterId="LD2n", `LD2`=c(-Inf,-7000)) 
 
RA=-40/180*pi 
Tfs <- transform(fs, `LD` = (cos(RA)*`FSC-A` - sin(RA)*`SSC-A`),`LD2` 
= (sin(RA)*`FSC-A` + cos(RA)*`SSC-A`)) 
Tfscom <- transform(fscom, `LD` = (cos(RA)*`FSC-A` - sin(RA)*`SSC-
A`),`LD2` = (sin(RA)*`FSC-A` + cos(RA)*`SSC-A`)) 
 
#compensation 
#PosTFS <- Subset(Tfs, morphGate & rectGate2 & rectGate)   
#PosTFScom <- Subset(Tfscom, morphGate & rectGate2 & rectGate)   
 
 
PosTFS <- Subset(Tfs, rectGate)   
PosTFS <- Subset(PosTFS, rectGate2)   
PosTFS <- Subset(PosTFS, morphGate)   
PosTFScom <- Subset(Tfscom, rectGate)   
PosTFScom <- Subset(PosTFScom, rectGate2)   
PosTFScom <- Subset(PosTFScom, morphGate)   
 
pdf("ld_data102610.pdf") 
opar <- par(mfrow=c(2, 2), mar=c(4,4,2,2))  
for (i in 1:8) {  
   # Plot results from rectangular and morphology gate  
plot(Tfs[[i]], c("LD", "LD2"),  
    xlab = "LD", xlim = c(0,150000), ylab = "LD2", ylim = c(-
30000,40000),  
    nrpoints = 1000) 
lines(c(0,150000),c(000,000)) 
} 
dev.off() 
 
Total <- as.numeric(fsApply(fs, nrow, use.exprs = TRUE)) 
MaxTime <- as.numeric(fsApply(fs, each_col, max))[1:length(fs)] 
Dens <- Total/MaxTime 
 
Live <- as.numeric(fsApply(PosTFS, nrow, use.exprs = TRUE)) 
DensLiv <- Live/MaxTime 
 
data1 <- data.frame("Files" = Tclist, "Total Cells" = Total,  
        "Live Cells" = Live, "Cell Dens" = Dens, "Live Dens" = 
DensLiv) 
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data1 <- transform(data1, `Percent` = data1[,3]*100/data1[,2])  
 
tabS1 <- as.matrix(data1) 
write.csv(tabS1, file="cellviability 102610.csv") 
 
#jpeg("fscsscvs1.jpg") 
pdf("data102610.pdf",width=8.5,height=11) 
opar <- par(mfrow=c(2,2), mar=c(4,4,2,2))  
 
Ptxt = Tclist 
for (i in 1:42) {  
   # Plot results from rectangular and morphology gate  
    plot(fs[[i]], c('FSC-A', 'SSC-A'),  
        xlab = "FSC", xlim = c(0,262144),  
        ylab = "SSC", ylim = c(0,262144),  
        nrpoints = 1000)  
    title(main=Ptxt[i], outer = FALSE, adj=0, cex.main = 1) 
 
    # Calculate 2-dimensional marginalized densities 
    lims1 <- c(0,262144,0,262144) 
    N.density <- kde2d(exprs(PosTFS[[i]][,2]),exprs(PosTFS[[i]][,3]), 
n=361, lims=lims1) 
 
    # Superimpose 100% contour lines on scatter plots 
    contour(N.density, levels=c(1e-10), add=TRUE, col="red", 
labels="95", lwd=3) 
} 
 
nspill.mat <- description(PosTFS[[1]])$SPILL 
nspill.mat 
 
# these need to be specified in a particular order 
# 1. unstained control 
# 2. single stain for first column after SSC-A 
# 3. single stain for second column after SSC-A 
# etc 
#Use a kmeansFilter to select high expression groups 
# use data set '04' for compensation calculation because the first 4 
is signle stain control 
#kmfilt1 <- kmeansFilter(filterId="kmfilt1", "FITC-A" = c("Low", 
"High")) 
#FITC04.high <- fsApply(PosTFS04[2], function(x) split(x, 
kmfilt1)$High) 
#FITC.high <- PosTFScom[2] 
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#kmfilt2 <- kmeansFilter(filterId="kmfilt2", "PE-A" = c("Low", 
"High")) 
#PE04.high <- fsApply(PosTFS04[3], function(x) split(x, 
kmfilt2)$High) 
#PE.high <-  PosTFScom[3]  
 
#kmfilt3 <- kmeansFilter(filterId="kmfilt3", "Alexa 647-A" = c("Low", 
"High")) 
#ALEXA04.high <- fsApply(PosTFS04[4], function(x) split(x, 
kmfilt3)$High) 
 
#Combine resulting flowFrames into a flowSet 
FiltFS = PosTFScom[c(1:3)] 
#FiltFS = flowSet(PosTFScom[[1]],FITC.high[[1]], PE.high[[1]], 
PerCP.high[[1]], ALEXA.high[[1]]) 
 
 
 
#Calculate the background intensity for each parameter 
#CMed = as.matrix(fsApply(FiltFS, each_col, median)[,-c(1:3)]) 
CMed = as.matrix(fsApply(FiltFS, each_col, median)[,-c(1:3,6,7)]) 
#CMed04 = as.matrix(fsApply(FiltFS04, each_col, median)[,-c(1:4)]) 
 
 
#Sweep out medians determined from unstained control from single 
stained 
#controls 
#bFiltFS <- transform(FiltFS, `FITC-A`=`FITC-A` - min(CMed[,1]), `PE-
A`=`PE-A`-min(CMed[,2]),`PerCP-Cy5-5-A`=`PerCP-Cy5-5-A`-
min(CMed[,3]), 
#    `Alexa 647-A`=`Alexa 647-A`-min(CMed[,4])) 
bFiltFS <- transform(FiltFS, `FITC-A`=`FITC-A` - min(CMed[,1]),  
    `Alexa 647-A`=`Alexa 647-A`-min(CMed[,2])) 
 
 
 
#Capture medians from single-stained flowFrames 
#FObs04 = as.matrix(fsApply(bFiltFS04[c(2:4)], each_col, median)[,-
c(1:4,6:7)]) 
FObs = as.matrix(fsApply(bFiltFS[c(2:3)], each_col, median)[,-
c(1:3,6:7)]) 
#For the FObs matrix, when the one for the particular experiment does 
not work (as in this case) 
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#FObs <- read.csv(file="FObs.csv",header=TRUE,sep=","); 
FObs 
 
#Estimate compensation spillover matrix 
fij = solve(FObs) %*% diag(diag(FObs)) 
#fij04 = solve(FObs04) %*% diag(diag(FObs04)) 
 
#Display new spillover matrix 
 
#When there is spillover of IL12 into pSTAT4 channel 
#fij <- read.csv(file="nspill060810.csv",header=TRUE,sep=","); 
fij 
 
# Apply calculated compensation matrix to compensation 
bPos2D6com <- transform(PosTFScom, `FITC-A`=`FITC-A` - min(CMed[,1]), 
    `Alexa 647-A`=`Alexa 647-A`-min(CMed[,2])) 
cPos2D6com <- transform(bPos2D6com,  
    `cFITCA`=fij[1,1]*`FITC-A` + fij[2,1]*`Alexa 647-A`,  
    `cAlexa647A`=fij[1,2]*`FITC-A` + fij[2,2]*`Alexa 647-A`) 
#apply to whole flow set 
bPos2D6 <- transform(PosTFS, `FITC-A`=`FITC-A` - min(CMed[,1]), 
    `Alexa 647-A`=`Alexa 647-A`-min(CMed[,2])) 
cPos2D6 <- transform(bPos2D6,  
    `cFITCA`=fij[1,1]*`FITC-A` + fij[2,1]*`Alexa 647-A`, 
    `cAlexa647A`=fij[1,2]*`FITC-A`+ fij[2,2]*`Alexa 647-A`) 
 
 
linlogTransform = function(transformationId, median = 0, dist = 1, 
...)  
{ 
    tr <- new("transform", .Data = function(x){  
        idx = which(x <= median + dist) 
        idx2 = which(x > median + dist) 
        if (length(idx2) > 0) { 
          x[idx2] = log10(x[idx2] - median) - log10(dist/exp(1))  
        } 
        if (length(idx) > 0) { 
          x[idx] = 1/dist * log10(exp(1))*(x[idx] - median)  
        } 
        x 
    }) 
    tr@transformationId = transformationId 
    tr 
}  
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lnlgT <- linlogTransform(transformationId="splitscale", median=0, 
dist=100) 
 
#Calculate X-labels for graphs 
lnlgTGraphs <- linlogTransform(transformationId="splitscale", 
median=0, dist=100) 
Xloc <- lnlgTGraphs(c(-200, -150, -100, -50, 0, 50, 100, 150, 200,  
    250, 400, 550, 700, 850, 1000,  
    2500, 4000, 5500, 7000, 8500, 10000,  
    25000, 40000, 55000, 70000, 85000, 100000)) 
Xlab <- c(-200,' ',-100,' ',0,' ',100, ' ', ' ', ' ', ' ', ' ', ' ', 
' ',  
    expression(10^3), ' ', ' ', ' ', ' ', ' ', expression(10^4),  
    ' ', ' ', ' ', ' ', ' ', expression(10^5)) 
 
cPos2D6com <- transform(cPos2D6com, `IL12RB2`=lnlgT(`cFITCA`),  
    `pSTAT4`=lnlgT(`cAlexa647A`))  
 
cPos2D6 <- transform(cPos2D6, `IL12RB2`=lnlgT(`cFITCA`),  
    `pSTAT4`=lnlgT(`cAlexa647A`))  
 
 
#get 'B1/B2', 'S4/B2' and 'S4/B1' 
cPos2D6com <- transform(cPos2D6com, `S4B2`=`cAlexa647A`/`cFITCA`)  
 
cPos2D6 <- transform(cPos2D6, `S4B2`=`cAlexa647A`/`cFITCA`)  
 
Plim = c(-0.5, 2.25) 
#Set up themes for all subsequent lattice figures 
trellis.par.set(theme = col.whitebg()) 
lw <- list(ylab.axis.padding = list(x = 0.5), 
        left.padding = list(x = 0.1, units = "inches"), 
        right.padding = list(x = 0, units = "inches"), 
        panel = list(x = 1.5, units = "inches")) 
lh <- list(bottom.padding = list(x = 0, units = "inches"), 
        top.padding <- list(x = 0, units = "inches"), 
        panel = list(x = 1.5, units = "inches")) 
 
lattice.options(layout.widths = lw, layout.heights = lh) 
 
cPos2D6com2 <- Subset(cPos2D6com, 
rectangleGate(filterId="fpSTAT4",`pSTAT4`=c(-3,Inf))) 
fsApply(cPos2D6com2, nrow) 
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# Plot results from spillover compensation 
#tp1 <-  xyplot(`IL12RB2`~`IL12RB1`|name, cPos2D6com2[c(1:5)], 
nrpoints = 1000,  
#        labels = FALSE, layout=c(1, 5), aspect=1,  
#        xlab = "IL12RB1", xlim = Plim, ylab = "IL12RB2", ylim = 
Plim, 
#        scales = list(x = list(at=Xloc, labels=Xlab),  
#        y = list(at=Xloc, labels=Xlab, rot=0)), 
#        strip = strip.custom(factor.levels = Tclistcom[c(1:5)]), 
#        panel = function(x, frames, channel.x, channel.y, ...){ 
#            panel.xyplot.flowset(x, frames, channel.x, channel.y, 
...) 
#            llines(c(-0.5,2.5),c(0,0)) 
#            llines(c(0,0),c(-0.5,2.5)) 
#        }) 
 
#tp2 <-  xyplot(`pSTAT4`~`IL12RB1`|name, cPos2D6com2[c(1:5)], 
nrpoints = 1000,  
#        labels = FALSE, layout=c(1, 5), aspect = 1, 
#        xlab = "IL12RB1", xlim = Plim, ylab = "pSTAT4", ylim = Plim, 
#        scales = list(x = list(at=Xloc, labels=Xlab),  
#        y = list(at=Xloc, labels=Xlab, rot=0)), 
#        strip = strip.custom(factor.levels = Tclistcom[c(1:5)]), 
#        panel = function(x, frames, channel.x, channel.y, ...){ 
#            panel.xyplot.flowset(x, frames, channel.x, channel.y, 
...) 
#            llines(c(-0.5,2.5),c(0,0)) 
#            llines(c(0,0),c(-0.5,2.5)) 
#        }) 
 
tp3 <-  xyplot(`IL12RB2`~`pSTAT4`|name, cPos2D6com2[c(1:3)], nrpoints 
= 1000,  
        labels = FALSE, layout=c(1, 3), aspect = 1, 
        xlab = "pSTAT4", xlim = Plim, ylab = "IL12RB2", ylim = Plim, 
        scales = list(x = list(at=Xloc, labels=Xlab),  
        y = list(at=Xloc, labels=Xlab, rot=0)), 
#        strip = strip.custom(factor.levels = Tclistcom[c(1:3)]), 
        panel = function(x, frames, channel.x, channel.y, ...){ 
            panel.xyplot.flowset(x, frames, channel.x, channel.y, 
...) 
            llines(c(-0.5,2.5),c(0,0)) 
            llines(c(0,0),c(-0.5,2.5)) 
        }) 
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#jpeg(filename = "2D6-SS.jpg", width = 1024, height = 1024) 
#pdf("2D6-SS.pdf") 
# plot(tp1, position = c(0, 0, 0.33, 1), more=TRUE) 
# plot(tp2, position = c(0.33, 0, 0.66, 1), more=TRUE) 
 plot(tp3, more=FALSE) 
#source("filename") 
#dev.off() # End plot  
 
 
#####################################################################
############################################################ 
 
 
#define positive limits 
# IL12RB2 - from Unstained control experiment 
RB21 <- density(exprs(cPos2D6com[[1]])[,10]) 
CumV <- 0 
limRB21 <- 0 
while (CumV < 0.95){ 
    limRB21 <- limRB21 + 1 
    CumV <- sum(RB21$y[1:limRB21])/sum(RB21$y) 
} 
 
# IL12RB2 - from pSTAT4 single-stained control experiment 
RB23 <- density(exprs(cPos2D6com[[3]])[,10]) 
CumV <- 0 
limRB23 <- 0 
while (CumV < 0.95){ 
    limRB23 <- limRB23 + 1 
    CumV <-sum(RB23$y[1:limRB23])/sum(RB23$y) 
} 
ValRB2 <- max(c(RB21$x[limRB21],RB23$x[limRB23])) 
 
#define positive limits 
# pSTAT4 - from unstimulated control experiment1 
S41 <- density(exprs(cPos2D6com[[1]])[,11]) 
CumV <- 0 
limS41 <- 0 
while (CumV < 0.95){ 
    limS41 <- limS41 + 1 
    CumV <- sum(S41$y[1:limS41])/sum(S41$y) 
} 
 
 62 
 
# pSTAT4 - from unstimulated control experiment2 
S42 <- density(exprs(cPos2D6[[2]])[,11]) 
CumV <- 0 
limS42 <- 0 
while (CumV < 0.95){ 
    limS42 <- limS42 + 1 
    CumV <- sum(S42$y[1:limS42])/sum(S42$y) 
} 
 
ValSTAT4 <- max(c(S41$x[limS41],S42$x[limS42])) 
 
tp1 <-  xyplot(`pSTAT4`~`IL12RB2`|name, cPos2D6com[c(1,2,3)], 
nrpoints = 1000,  
        labels = FALSE, layout=c(1, 3), aspect=1,  
        xlab = "IL12RB2", xlim = Plim, ylab = "pSTAT4", ylim = Plim, 
        scales = list(x = list(at=Xloc, labels=Xlab),  
        y = list(at=Xloc, labels=Xlab, rot=0)), 
        #strip = strip.custom(factor.levels = Tclistcom[c(1,2,3)]), 
        panel = function(x, frames, channel.x, channel.y, ...){ 
            panel.xyplot.flowset(x, frames, channel.x, channel.y, 
...) 
            llines(c(0,0),c(-1,2.75)) 
            llines(c(-1,2.75), c(0,0),lty=2) 
        }) 
 
             
plot(tp1, position = c(0, 0, 1, 1), more=FALSE) 
 
tr1 <-  xyplot(`pSTAT4`~`IL12RB2`|factor(name,levels=unique(name)), 
cPos2D6[c(1:12)], nrpoints = 1000,  
        labels = FALSE, layout=c(3,4), aspect=1,  
        xlab = "IL12RB2", xlim = Plim, ylab = "pSTAT4", ylim = Plim, 
        scales = list(x = list(at=Xloc, labels=Xlab),  
        y = list(at=Xloc, labels=Xlab, rot=0)), 
        #strip = strip.custom(factor.levels = 
Tclist[c(1,4,7,10,13,16)]), 
        panel = function(x, frames, channel.x, channel.y, ...){ 
            panel.xyplot.flowset(x, frames, channel.x, channel.y, 
...) 
            llines(c(ValRB2,ValRB2),c(-1,2.75)) 
            llines(c(-1,2.75), c(ValSTAT4,ValSTAT4),lty=2) 
        }) 
 
tr2 <-  xyplot(`pSTAT4`~`IL12RB2`|factor(name,levels=unique(name)), 
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cPos2D6[c(13:24)], nrpoints = 1000,  
        labels = FALSE, layout=c(3,4), aspect=1,  
        xlab = "IL12RB2", xlim = Plim, ylab = "pSTAT4", ylim = Plim, 
        scales = list(x = list(at=Xloc, labels=Xlab),  
        y = list(at=Xloc, labels=Xlab, rot=0)), 
        #strip = strip.custom(factor.levels = 
Tclist[c(2,5,8,11,14,17)]), 
        panel = function(x, frames, channel.x, channel.y, ...){ 
            panel.xyplot.flowset(x, frames, channel.x, channel.y, 
...) 
            llines(c(ValRB2,ValRB2),c(-1,2.75)) 
            llines(c(-1,2.75), c(ValSTAT4,ValSTAT4),lty=2) 
        }) 
 
tr3 <-  xyplot(`pSTAT4`~`IL12RB2`|factor(name,levels=unique(name)), 
cPos2D6[c(25:42)], nrpoints = 1000,  
        labels = FALSE, layout=c(3,4), aspect=1,  
        xlab = "IL12RB2", xlim = Plim, ylab = "pSTAT4", ylim = Plim, 
        scales = list(x = list(at=Xloc, labels=Xlab),  
        y = list(at=Xloc, labels=Xlab, rot=0)), 
        #strip = strip.custom(factor.levels = 
Tclist[c(3,6,9,12,15)]), 
        panel = function(x, frames, channel.x, channel.y, ...){ 
            panel.xyplot.flowset(x, frames, channel.x, channel.y, 
...) 
            llines(c(ValRB2,ValRB2),c(-1,2.75)) 
            llines(c(-1,2.75), c(ValSTAT4,ValSTAT4),lty=2) 
        }) 
 
                         
plot(tr1)#position = c(0, 0, 0.33, 1), more=TRUE) 
plot(tr2)# position = c(0.34, 0, 0.66, 1), more=TRUE) 
plot(tr3)# position = c(0.67, 0, 1, 1), more=FALSE) 
             
# For histogram 
 
yrng<-c(0,2.5) 
xrng<-c(-0.5,2.5) 
opar<-par(mfcol=c(2,2),mar=c(4,4,2,2)) 
Pidx=c(1,4,7,10) 
Plty=c(1,2,3,4) 
Pcols<-c("red","darkgreen","blue","black") 
plot(density(exprs(cPos2D6[[Pidx[1]]])[,11],na.rm=TRUE,kernel="rect")
, 
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 col=Pcols[1],xlab="pSTAT4",xlim=xrng,ylab="Density", 
 main="",ylim=yrng,xaxt="n",lwd=2,lty=1) 
title(main="A",outer=FALSE,adj=0,cex.main=1) 
axis(1,Xloc,labels=Xlab) 
for(i in 2:length(Pidx)){ 
 lines(density(exprs(cPos2D6[[Pidx[i]]])[,11],na.rm=TRUE, 
  kernel="rect"),col=Pcols[i],lwd=2,lty=Plty[i]) 
#Plot Beta 2 
pdf("B2-histograms102610.pdf", width = 6.25, height = 6.25) 
plot(density(exprs(cPos2D6com[[19]])[,10], na.rm = TRUE), type = "n", 
    col=1, xlab = expression(paste("IL-12R",beta,"2 (MFI)")), xlim = 
c(-0.5,2.0), xaxt = "n",  
    ylab ="Normalized Density", ylim = c(0,1),main = "") 
BG = density(exprs(cPos2D6com[[1]])[,10], na.rm=TRUE, from = -0.5, to 
= 2) 
polygon(BG$x, BG$y/max(BG$y), col=gray(0.7)) 
#lines(BG$x, BG$y/max(BG$y), col=gray(0.7), lwd=2, lty=1) 
L1 <- density(exprs(cPos2D6com[[2]])[,10], na.rm=TRUE, from = -0.5, 
to = 2) 
lines(L1$x, L1$y/max(L1$y), col="black", lwd=2, lty=1) 
L2 <- density(exprs(cPos2D6com[[3]])[,10], na.rm=TRUE, from = -0.5, 
to = 2) 
lines(L2$x, L2$y/max(L2$y), col="red", lwd=2, lty=1) 
axis(1, Xloc, labels=Xlab)    
dev.off() 
 
#Plot pSTAT4 
pdf("pSTAT4-histograms102610.pdf", width = 6.25, height = 6.25) 
plot(density(exprs(cPos2D6com[[1]])[,11], na.rm = TRUE), type = "n", 
    col=1, xlab = expression(paste("pSTAT"," 4 (MFI)")), xlim = c(-
0.5,2.0), xaxt = "n",  
    ylab ="Normalized Density", ylim = c(0,1),main = "") 
BG = density(exprs(cPos2D6com[[1]])[,11], na.rm=TRUE, from = -0.5, to 
= 2) 
polygon(BG$x, BG$y/max(BG$y), col=gray(0.7)) 
#lines(BG$x, BG$y/max(BG$y), col=gray(0.7), lwd=2, lty=1) 
L1 <- density(exprs(cPos2D6com[[2]])[,11], na.rm=TRUE, from = -0.5, 
to = 2) 
lines(L1$x, L1$y/max(L1$y), col="black", lwd=2, lty=1) 
L2 <- density(exprs(cPos2D6com[[3]])[,11], na.rm=TRUE, from = -0.5, 
to = 2) 
lines(L2$x, L2$y/max(L2$y), col="red", lwd=2, lty=1) 
axis(1, Xloc, labels=Xlab)    
dev.off() 
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} 
 
 
#use the B2 possitive gate defined before   
#rectB2Gate <- rectangleGate(filterId="cFITC+",`cFITC`=c(300,500)) 
#RB2PGate <- 
rectangleGate(filterId="IL12RB2+",`IL12RB2`=c(ValRB2,Inf))  
#RB2P = Subset(cPos2D6, RB2PGate) 
#RB2P04 = Subset(cPos2D604, rectB2Gate) 
#RB2P524 = Subset(cPos2D6524, rectB2Gate) 
     
Total = vector('list',42) 
mRB2 = vector('list',42) 
mSTAT4 = vector('list',42) 
mS4B2 = vector('list',42) 
 
# use the compensation numbers here show statistic [10],[11],[12]and 
[18],[19],[20] 
for (i  in 1:42) { 
    Total[[i]] <- nrow(cPos2D6[[i]]) 
    mRB2[[i]] <- fsApply(cPos2D6[i], each_col, median)[,10] 
    mSTAT4[[i]] <- fsApply(cPos2D6[i], each_col, median)[,11] 
    mS4B2[[i]] <- fsApply(cPos2D6[i], each_col, median)[,12] 
 } 
 
#summary(cPos2D6com2[[4]])#to view matrix with values 
 
data31 <- data.frame("Experiment" = Tclist[c(1:42)],  
    "Total Cells" = as.numeric(Total),  
    "MFI IL12RB2" = as.numeric(mRB2), 
    "MFI pSTAT4" = as.numeric(mSTAT4), 
    "MFI S4B2" = as.numeric(mS4B2))  
 
tab31<- as.matrix(data31) 
 
tab31 
 
dev.off() # End plot 
 
summary (cPos2D6) 
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APPENDIX B 
 
Representative no stain and single stain control plots 
 
Figure 1. Single stain controls for pSTAT4 and IL-12Rβ2 used for compensation 
by representing each one a positive signal in its own channel only. Top panels 
are no stain controls, middle left and bottom right are single stain controls for 
IL-12Rβ2, and middle right and bottom left are single stain controls for pSTAT4. 
 
 
 
 
 
 
 
 
 
 67 
 
 
APPENDIX C 
 
Statistical analysis of treatment groups 
 
 
1. Effect of TGF-β on pSTAT4 
 
1.1 Effect of TGF-β after 15 minutes 
 
Two-way ANOVA: pSTAT4 versus TGF-beta; IL-12  
 
Source       DF       SS       MS      F      P 
TGF-beta      1   42,075   42,075   6,77  0,031 
IL-12         1  325,833  325,833  52,46  0,000 
Interaction   1   25,667   25,667   4,13  0,077 
Error         8   49,688    6,211 
Total        11  443,263 
 
S = 2,492   R-Sq = 88,79%   R-Sq(adj) = 84,59% 
 
 
1.2 Effect of TGF-β after 1 hour 
 
Two-way ANOVA: pSTAT4 versus TGF-beta; IL-12  
 
Source       DF       SS       MS     F      P 
TGF-beta      1   257,75  257,752  1,46  0,262 
IL-12         1   486,60  486,604  2,75  0,136 
Interaction   1    51,32   51,315  0,29  0,605 
Error         8  1415,78  176,973 
Total        11  2211,46 
 
S = 13,30   R-Sq = 35,98%   R-Sq(adj) = 11,97% 
 
 
1.3 Effect of TGF-β after 2 hours 
 
Two-way ANOVA: pSTAT4 versus TGF-beta; IL-12  
 
Source       DF       SS       MS       F      P 
TGF-beta      1  1842,89  1842,89  103,08  0,000 
IL-12         1  4681,15  4681,15  261,84  0,000 
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Interaction   1   925,59   925,59   51,77  0,000 
Error         8   143,02    17,88 
Total        11  7592,64 
 
S = 4,228   R-Sq = 98,12%   R-Sq(adj) = 97,41% 
 
 
2. Effect of TGF-β on cell viability 
 
2.1 Effect of TGF-β after 15 minutes 
 
Two-way ANOVA: Live cell percent versus TGF-beta; IL-12  
 
Source       DF       SS       MS     F      P 
TGF-beta      1    0,074   0,0736  0,01  0,939 
IL-12         1   19,051  19,0512  1,63  0,237 
Interaction   1   16,709  16,7088  1,43  0,265 
Error         8   93,233  11,6541 
Total        11  129,066 
 
S = 3,414   R-Sq = 27,76%   R-Sq(adj) = 0,68% 
 
 
2.2 Effect of TGF-β after 1 hour 
 
Two-way ANOVA: Live cell percent versus TGF-beta; IL-12  
 
Source       DF       SS       MS     F      P 
TGF-beta      1  251,534  251,534  9,85  0,014 
IL-12         1    2,595    2,595  0,10  0,758 
Interaction   1   77,216   77,216  3,02  0,120 
Error         8  204,232   25,529 
Total        11  535,576 
 
S = 5,053   R-Sq = 61,87%   R-Sq(adj) = 47,57% 
 
 
2.3 Effect of TGF-β after 2 hours 
 
Two-way ANOVA: Live cell percent versus TGF-beta; IL-12  
 
Source       DF       SS       MS      F      P 
TGF-beta      1  256,364  256,364  22,41  0,001 
IL-12         1  124,775  124,775  10,91  0,011 
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Interaction   1  164,317  164,317  14,36  0,005 
Error         8   91,516   11,439 
Total        11  636,972 
 
S = 3,382   R-Sq = 85,63%   R-Sq(adj) = 80,24% 
 
 
 
3.  Effect of time and treatment with insulin 
 
3.1 Effect of Insulin after 15 minutes 
 
Two-way ANOVA: pSTAT4 versus Insulin; IL-12  
 
Source       DF       SS       MS     F      P 
Insulin       1    2,253    2,253  0,17  0,694 
IL-12         1  126,750  126,750  9,38  0,016 
Interaction   1   36,053   36,053  2,67  0,141 
Error         8  108,160   13,520 
Total        11  273,217 
 
S = 3,677   R-Sq = 60,41%   R-Sq(adj) = 45,57% 
 
 
3.2 Effect of Insulin after 1 hour 
 
Two-way ANOVA: pSTAT4 versus Insulin; IL-12  
 
Source       DF       SS       MS       F      P 
Insulin       1   29,610   29,610    6,62  0,033 
IL-12         1  498,585  498,585  111,50  0,000 
Interaction   1   65,100   65,100   14,56  0,005 
Error         8   35,772    4,471 
Total        11  629,067 
 
S = 2,115   R-Sq = 94,31%   R-Sq(adj) = 92,18% 
 
 
2.3 Effect of Insulin after 2 hours 
 
Two-way ANOVA: pSTAT4 versus Insulin; IL-12  
 
Source       DF       SS       MS       F      P 
Insulin       1     1,73     1,73    0,54  0,484 
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IL-12         1  1128,11  1128,11  352,10  0,000 
Interaction   1    65,10    65,10   20,32  0,002 
Error         8    25,63     3,20 
Total        11  1220,57 
 
S = 1,790   R-Sq = 97,90%   R-Sq(adj) = 97,11% 
 
 
  
4. Effect of insulin on cell viability 
 
4.1 Effect of Insulin after 15 minutes 
 
Two-way ANOVA: Live cell percent versus Insulin; IL-12  
 
Source       DF       SS       MS     F      P 
Insulin       1   0,0001  0,00013  0,00  0,995 
IL-12         1   3,8307  3,83070  1,17  0,311 
Interaction   1   2,8421  2,84213  0,87  0,379 
Error         8  26,1760  3,27200 
Total        11  32,8490 
 
S = 1,809   R-Sq = 20,31%   R-Sq(adj) = 0,00% 
 
 
4.2 Effect of Insulin after 1 hour 
 
Two-way ANOVA: Live cell percent versus Insulin; IL-12  
 
Source       DF       SS       MS     F      P 
Insulin       1  20,4363  20,4363  5,78  0,043 
IL-12         1   6,9921   6,9921  1,98  0,197 
Interaction   1   1,0208   1,0208  0,29  0,606 
Error         8  28,2636   3,5329 
Total        11  56,7129 
 
S = 1,880   R-Sq = 50,16%   R-Sq(adj) = 31,48% 
 
 
4.3 Effect of Insulin after 2 hours 
 
Two-way ANOVA: Live cell percent versus Insulin; IL-12  
 
Source       DF       SS       MS     F      P 
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Insulin       1    6,571   6,5712  0,89  0,374 
IL-12         1   24,596  24,5960  3,31  0,106 
Interaction   1   40,333  40,3333  5,43  0,048 
Error         8   59,386   7,4233 
Total        11  130,887 
 
S = 2,725   R-Sq = 54,63%   R-Sq(adj) = 37,61 
 
 
5. Effect of IL-6 on pSTAT4 
 
5.1 Effect of IL-6 after 15 minutes 
 
Two-way ANOVA: pSTAT4 versus IL-6; IL-12  
 
Source       DF       SS       MS     F      P 
IL-6          1  266,492  266,492  4,18  0,075 
IL-12         1    0,317    0,317  0,00  0,946 
Interaction   1   59,185   59,185  0,93  0,364 
Error         8  510,098   63,762 
Total        11  836,092 
 
S = 7,985   R-Sq = 38,99%   R-Sq(adj) = 16,11% 
 
 
5.2 Effect of IL-6 after 1 hour 
 
Two-way ANOVA: pSTAT4 versus IL-6; IL-12  
 
Source       DF       SS       MS      F      P 
IL-6          1     2,25    2,253   0,07  0,794 
IL-12         1   225,33  225,333   7,27  0,027 
Interaction   1   813,45  813,453  26,25  0,001 
Error         8   247,87   30,983 
Total        11  1288,91 
 
S = 5,566   R-Sq = 80,77%   R-Sq(adj) = 73,56% 
 
 
5.3 Effect of IL-6 after 2 hours 
 
Two-way ANOVA: pSTAT4 versus IL-6; IL-12  
 
Source       DF       SS       MS      F      P 
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IL-6          1   25,667   25,667   2,31  0,167 
IL-12         1   71,297   71,297   6,43  0,035 
Interaction   1  198,047  198,047  17,86  0,003 
Error         8   88,725   11,091 
Total        11  383,736 
 
S = 3,330   R-Sq = 76,88%   R-Sq(adj) = 68,21% 
 
 
6.  Effect of IL-6 on cell viability 
 
6.1 Effect of IL-6 after 15 minutes 
 
Two-way ANOVA: Live cell percent versus IL-6; IL-12  
 
Source       DF       SS       MS     F      P 
IL-6          1    1,279   1,2793  0,07  0,798 
IL-12         1    0,001   0,0012  0,00  0,994 
Interaction   1   10,143  10,1427  0,56  0,477 
Error         8  145,589  18,1987 
Total        11  157,012 
 
S = 4,266   R-Sq = 7,28%   R-Sq(adj) = 0,00% 
 
6.2 Effect of IL-6 after 1 hour 
 
Two-way ANOVA: Live cell percent versus IL-6; IL-12  
 
Source       DF       SS       MS     F      P 
IL-6          1   34,525  34,5252  3,66  0,092 
IL-12         1   32,019  32,0193  3,39  0,103 
Interaction   1   18,893  18,8925  2,00  0,195 
Error         8   75,493   9,4366 
Total        11  160,930 
 
S = 3,072   R-Sq = 53,09%   R-Sq(adj) = 35,50% 
 
6.3 Effect of IL-6 after 2 hours 
 
Two-way ANOVA: Live cell percent versus IL-6; IL-12  
 
Source       DF       SS       MS     F      P 
IL-6          1   38,815  38,8149  1,86  0,210 
IL-12         1   14,881  14,8809  0,71  0,423 
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Interaction   1   59,972  59,9718  2,87  0,129 
Error         8  167,328  20,9160 
Total        11  280,996 
 
S = 4,573   R-Sq = 40,45%   R-Sq(adj) = 18,12% 
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APPENDIX D 
 
Protocol for Western Blot 
 
Gel Electrophoresis 
 
1. Place larger glass sheet on bottom (back) and shorter on top (front) and align 
using black rubber strips (spacers) on sides. 
 
2. Place glasses vertically on holder, press edges to align. 
 
3. Tighten screws up to first resistance (when too tight, it can leak) 
 
4. Snap onto base and add water to check for leaks. 
 
5. Prepare resolving gel using recipe for 5ml (for 1 gel) or 10 ml (for 2 gels) and 12% 
acrilamide. 
 
6. Pour resolving gel up to hinges on sides, and add a bit of water on top to take care 
of bubbles (up to top). 
 
7. Let polymerize for 40 minutes. 
 
8. Pour off water from the top of glasses. 
 
9. Prepare 1 or 2 ml of stacking gel as indicated on recipe and pour it on top of 
resolving gel. 
 
10. Put comb in between glasses right after pouring gel. 
 
11. After 30 minutes, remove comb upright and wash wells with 1x running buffer. 
 
12. Snap glass holder on unit and pour 1x buffer in inner chamber first, and then fill 
up the rest of the chamber. 
 
13. Add SDS 4x buffer to protein samples for a complete volume of 40 μl, and boil 
samples for 3 minutes. 
 
14. Pour samples, controls and ladder into the wells making sure it settles on the 
bottom. 
 
15. Close chamber and connect to voltage source. 
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16. Run at 75V, 350 mA (6h) for 2 hours. 
 
 
 
Transfer 
 
1. Cut four 6 x 9 com pieces of blot paper and one 6 x 9 cm piece of membrane for 
the transfer. 
 
2. Put cassette sandwich with black part down, then put foam piece on black lid and 
pour 1x Transfer Buffer, then put 2 transfer blot papers, then gel as mirror image on 
paper, then membrane on top with protein side marked, and repeat sequence in 
reverse order (Note: keep moist with 1x Transfer buffer at all times). 
 
3. Place cassette sandwich on unit, black side facing black walls of chamber, and 
white edge of cassette up. 
 
4. Place in bigger chamber, black wall in, with ice packet, and fill with buffer almost to 
top. 
 
5. Transfer at 42V for 1. 5 hours. 
 
Blotting 
 
1. After transfer is finished take membrane out of chamber and place in a WB box  to 
block for 1 hr with 10 ml of Odyssey Blocking Buffer and gentle shaking 
 
2. Put membrane in primary antibody solution (10 ml Blocking Buffer + 0.2% Tween 
20 + Phospho-Stat3 (Tyr705)-Cell Signaling Technology Inc.) and incubate overnight 
at 4°C and gentle shaking. 
 
3. Wash 4x with 10 ml of PBST (PBS + 0.1% Tween 20) for minutes. 
 
4. Put membrane in secondary antibody solution (10 ml Blocking Buffer + 0.2% 
Tween 20 + 0.01% SDS + secondary antibody (1:15,000)) and incubate for 1 hour at 
room temperature and gentle shaking (Note: Protect from light from this point on). 
 
5. Pour off solution and wash 4x with 10 ml of PBST. 
 
6. Rinse membrane with 1x PBS to remove residual Tween 20. 
 
7. Scan membrane in Li-Cor Infrared Odyssey Scanner. 
 
